Acylated N-(1 ,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)-aryl carboxamides, and use thereof as herbicides

10604494 ยท 2020-03-31

Assignee

Inventors

Cpc classification

International classification

Abstract

Acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides of the formula (I) and the use thereof as herbicides are described. ##STR00001## In this formula (I), R, V, X, Y and Z are radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halogen. Q is an oxadiazole, triazole or tetrazole radical. W is CY or N.

Claims

1. An acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- or N-(triazol-5-yl)arylcarboxamide, and/or a salt thereof, of formula (I) ##STR00022## wherein the symbols and indices are defined as follows: R is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-halocycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkyl-S(O).sub.nR.sup.2, (C.sub.1-C.sub.6)-alkyl-OR.sup.1, (C.sub.1-C.sub.6)-alkyl-OCOR.sup.1, (C.sub.1-C.sub.6)-alkyl-OSO.sub.2R.sup.2, (C.sub.1-C.sub.6)-alkyl-COOR.sup.1, (C.sub.1-C.sub.6)-alkyl-C(O)R.sup.1, (C.sub.1-C.sub.6)-alkyl-CN, (C.sub.1-C.sub.6)-alkyl-SO.sub.2OR.sup.1, (C.sub.1-C.sub.6)-alkyl-CON(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-SO.sub.2N(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-NR.sup.1COR.sup.1, (C.sub.1-C.sub.6)-alkyl-NR.sup.1SO.sub.2R.sup.2, COOR.sup.1, CON(R.sup.1).sub.2, or phenyl, heteroaryl, heterocyclyl or benzyl, each substituted by s radicals selected from the group consisting of X, Y, Z and V, W is N or CY, X and Z are each independently hydrogen, nitro, halogen, cyano, formyl, thiocyanato, (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-halocycloalkyl-(C.sub.1-C.sub.6)-alkyl, COR.sup.1, OR.sup.1, OCOR.sup.1, OSO.sub.2R.sup.2, S(O).sub.nR.sup.2, SO.sub.2OR.sup.1, SO.sub.2N(R.sup.1).sub.2, NR.sup.1SO.sub.2R.sup.2, NR.sup.1COR.sup.1, (C.sub.1-C.sub.6)-alkyl-S(O).sub.nR.sup.2, (C.sub.1-C.sub.6)-alkyl-OR.sup.1, (C.sub.1-C.sub.6)-alkyl-OCOR.sup.1, (C.sub.1-C.sub.6)-alkyl-OSO.sub.2R.sup.2, (C.sub.1-C.sub.6)-alkyl-COOR.sup.1, (C.sub.1-C.sub.6)-alkyl-SO.sub.2OR.sup.1, (C.sub.1-C.sub.6)-alkyl-CON(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-SO.sub.2N(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-NR.sup.1COR.sup.1, (C.sub.1-C.sub.6)-alkyl-NR.sup.1SO.sub.2R.sup.2, NR.sup.1R.sup.2, P(O)(OR.sup.5).sub.2, or heteroaryl, heterocyclyl or phenyl, each substituted by s radicals selected from the group consisting of methyl, ethyl, methoxy, nitro, trifluoromethyl and halogen, Y is hydrogen, nitro, halogen, cyano, thiocyanato, (C.sub.1-C.sub.6)-alkyl, halo-(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, halo-(C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, halo-(C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkenyl, halo-(C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, halo-(C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, COR.sup.1, COOR.sup.1, OCOOR.sup.1, NR.sup.1COOR.sup.1, C(O)N(R.sup.1).sub.2, NR.sup.1C(O)N(R.sup.1).sub.2, OC(O)N(R.sup.1).sub.2, C(O)N(R.sup.1)OR.sup.1, NR.sup.1SO.sub.2R.sup.2, NR.sup.1COR.sup.1, OR.sup.1, OSO.sub.2R.sup.2, S(O).sub.nR.sup.2, SO.sub.2OR.sup.1, SO.sub.2N(R.sup.1).sub.2 (C.sub.1-C.sub.6)-alkyl-S(O).sub.nR.sup.2, (C.sub.1-C.sub.6)-alkyl-OR.sup.1, (C.sub.1-C.sub.6)-alkyl-OCOR.sup.1, (C.sub.1-C.sub.6)-alkyl-OSO.sub.2R.sup.2, (C.sub.1-C.sub.6)-alkyl-CO.sub.2R.sup.1, (C.sub.1-C.sub.6)-alkyl-CN, (C.sub.1-C.sub.6)-alkyl-SO.sub.2OR.sup.1, (C.sub.1-C.sub.6)-alkyl-CON(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-SO.sub.2N(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-NR.sup.1COR.sup.1, (C.sub.1-C.sub.6)-alkyl-NR.sup.1SO.sub.2R.sup.2, N(R.sup.1).sub.2, P(O)(OR.sup.5).sub.2, CH.sub.2P(O)(OR.sup.5).sub.2, CHNOR.sup.1, (C.sub.1-C.sub.6)-alkyl-CHNOR.sup.1, (C.sub.1-C.sub.6)-alkyl-ONC(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkylphenyl, (C.sub.1-C.sub.6)-alkylheteroaryl, (C.sub.1-C.sub.6)-alkylheterocyclyl, phenyl, heteroaryl or heterocyclyl, where the 6 latter radicals are each substituted by s radicals selected from the group consisting of halogen, nitro, cyano, (C.sub.1-C.sub.6)-alkyl, halo-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl, S(O).sub.n-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy, halo-(C.sub.1-C.sub.6)-alkoxy, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.4)-alkyl and cyanomethyl, and where heterocyclyl bears n oxo groups, or Y and Z together with the two atoms to which they are bonded form a 5-, 6- or 7-membered, unsaturated, partly saturated or saturated ring which, as well as carbon atoms, in each case comprises s nitrogen atoms, n oxygen atoms, n sulfur atoms and n S(O), S(O).sub.2, CNR.sup.17, C(OR.sup.17).sub.2, C[O(CH.sub.2).sub.2O-] or C(O) elements as ring members, wherein the carbon atoms are substituted by s radicals selected from the group consisting of halogen, cyano, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.10)-alkenyl, (C.sub.2-C.sub.10)-alkynyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.1-C.sub.6)-alkoxy, phenoxy, halo-(C.sub.1-C.sub.6)-alkoxy, (C.sub.3-C.sub.8)-cycloalkyl, (C.sub.2-C.sub.8)-alkoxyalkyl and phenyl, wherein the nitrogen atoms are substituted by n radicals selected from the group consisting of (C.sub.1-C.sub.6)-alkyl and phenyl, and wherein the aforementioned phenyl radicals are substituted by s radicals selected from the group consisting of cyano, nitro, halogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl and (C.sub.1-C.sub.6)-alkoxy, V is hydrogen, nitro, halogen, cyano, (C.sub.1-C.sub.4)-alkyl, (C.sub.1-C.sub.4)-haloalkyl, OR.sup.1, S(O).sub.nR.sup.2, R.sup.1 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkenyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.1-C.sub.6)-alkyl-O(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, phenyl, phenyl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, (C.sub.1-C.sub.6)-alkylheteroaryl, heterocyclyl, (C.sub.1-C.sub.6)-alkylheterocyclyl, (C.sub.1-C.sub.6)-alkyl-O-heteroaryl, (C.sub.1-C.sub.6)-alkyl-O-heterocyclyl, (C.sub.1-C.sub.6)-alkyl-NR.sup.3-heteroaryl or (C.sub.1-C.sub.6)-alkyl-NR.sup.3-heterocyclyl, where the 21 latter radicals are substituted by s radicals selected from the group consisting of cyano, halogen, nitro, thiocyanato, OR.sup.3, S(O).sub.nR.sup.4, N(R.sup.3).sub.2, NR.sup.3OR.sup.3, COR.sup.3, OCOR.sup.3, SCOR.sup.4, NR.sup.3COR.sup.3, NR.sup.3SO.sub.2R.sup.4, CO.sub.2R.sup.3, COSR.sup.4, CON(R.sup.3).sub.2 and (C.sub.1-C.sub.4)-alkoxy-(C.sub.2-C.sub.6)-alkoxycarbonyl, and where heterocyclyl bears n oxo groups, R.sup.2 is (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkenyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.1-C.sub.6)-alkyl-O(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, phenyl, phenyl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, (C.sub.1-C.sub.6)-alkylheteroaryl, heterocyclyl, (C.sub.1-C.sub.6)-alkylheterocyclyl, (C.sub.1-C.sub.6)-alkyl-O-heteroaryl, (C.sub.1-C.sub.6)-alkyl-O-heterocyclyl, (C.sub.1-C.sub.6)-alkyl-NR.sup.3-heteroaryl, (C.sub.1-C.sub.6)-alkyl-NR.sup.3-heterocyclyl, where the 21 latter radicals are substituted by s radicals selected from the group consisting of cyano, halogen, nitro, thiocyanato, OR.sup.3, S(O).sub.nR.sup.4, N(R.sup.3).sub.2, NR.sup.3OR.sup.3, COR.sup.3, OCOR.sup.3, SCOR.sup.4, NR.sup.3COR.sup.3, NR.sup.3SO.sub.2R.sup.4, CO.sub.2R.sup.3, COSR.sup.4, CON(R.sup.3).sub.2 and (C.sub.1-C.sub.4)-alkoxy-(C.sub.2-C.sub.6)-alkoxycarbonyl, and where heterocyclyl bears n oxo groups, R.sup.3 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-cycloalkyl or (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, R.sup.4 is (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl or (C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-cycloalkyl or (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, R.sup.5 is (C.sub.1-C.sub.4)-alkyl, n is 0, 1 or 2, s is 0, 1, 2 or 3, Q is a Q1, Q2, Q3 or Q4 radical ##STR00023## R.sup.6 and R.sup.7 are independently (C.sub.1-C.sub.6)-alkyl, halo-(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, halo-(C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, or halo-(C.sub.2-C.sub.6)-alkynyl, where these 6 aforementioned radicals are each substituted by s radicals selected from the group consisting of nitro, cyano, SiR.sup.12.sub.3, PO(OR.sup.12).sub.3, S(O).sub.n-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy, halo-(C.sub.1-C.sub.6)-alkoxy, N(R.sup.10).sub.2, COR.sup.10, COOR.sup.10, OCOR.sup.10, OCO.sub.2R.sup.10, NR.sup.10COR.sup.10, NR.sup.10SO.sub.2R.sup.11, (C.sub.3-C.sub.6)-cycloalkyl, heteroaryl, heterocyclyl, phenyl, D-heteroaryl, D-heterocyclyl, D-phenyl or D-benzyl, and where the 7 latter radicals are substituted by s radicals selected from the group of methyl, ethyl, methoxy, trifluoromethyl and halogen, and where heterocyclyl bears n oxo groups, or R.sup.6 and R.sup.7 are each (C.sub.3-C.sub.7)-cycloalkyl, heteroaryl, heterocyclyl or phenyl, each substituted by s radicals selected from the group consisting of halogen, nitro, cyano, (C.sub.1-C.sub.6)-alkyl, halo-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl, S(O).sub.n(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy, halo-(C.sub.1-C.sub.6)-alkoxy and (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.4)-alkyl, R.sup.8 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl, halo-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy, halo-(C.sub.1-C.sub.6)-alkoxy, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkenyloxy, halo-(C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.2-C.sub.6)-alkynyloxy, halo-(C.sub.2-C.sub.6)-alkynyl, cyano, nitro, methylsulfenyl, methylsulfinyl, methylsulfonyl, (C.sub.1-C.sub.6)-alkylcarbonylamino, (C.sub.1-C.sub.6)-alkoxycarbonylamino, benzoylamino, methoxycarbonyl, ethoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, benzoyl, methylcarbonyl, piperidinylcarbonyl, trifluoromethylcarbonyl, halogen, amino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methoxymethyl, or heteroaryl, heterocyclyl or phenyl, each substituted by s radicals selected from the group consisting of methyl, ethyl, methoxy, trifluoromethyl and halogen; R.sup.9 is hydrogen, (C.sub.1-C.sub.6)-alkyl, R.sup.13O(C.sub.1-C.sub.6)-alkyl, CH.sub.2R.sup.14, (C.sub.3-C.sub.7)-cycloalkyl, halo-(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, halo-(C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, halo-(C.sub.2-C.sub.6)-alkynyl, OR.sup.13, NHR.sup.13, methoxycarbonyl, ethoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, methylcarbonyl, trifluoromethylcarbonyl, dimethylamino, acetylamino, methylsulfenyl, methylsulfinyl, methylsulfonyl, or heteroaryl, heterocyclyl, benzyl or phenyl, each substituted by s radicals selected from the group consisting of halogen, nitro, cyano, (C.sub.1-C.sub.6)-alkyl, halo-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl, S(O).sub.n(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy, halo-(C.sub.1-C.sub.6)-alkoxy and (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.4)-alkyl, R.sup.10 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-cycloalkyl or (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl or phenyl, R.sup.11 is (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl or phenyl, R.sup.12 is (C.sub.1-C)-alkyl, R.sup.13 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkenyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.1-C.sub.6)-alkyl-O(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, phenyl, phenyl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, (C.sub.1-C.sub.6)-alkylheteroaryl, heterocyclyl, (C.sub.1-C.sub.6)-alkylheterocyclyl, (C.sub.1-C.sub.6)-alkyl-O-heteroaryl, (C.sub.1-C.sub.6)-alkyl-O-heterocyclyl, (C.sub.1-C.sub.6)-alkyl-NR.sup.15-heteroaryl or (C.sub.1-C.sub.6)-alkyl-NR.sup.15-heterocyclyl, where the 21 latter radicals are substituted by s radicals selected from the group consisting of cyano, halogen, nitro, thiocyanato, OR.sup.15, S(O).sub.nR.sup.16, N(R.sup.15).sub.2, NR.sup.15OR.sup.15, COR.sup.15, OCOR.sup.15, SCOR.sup.16, NR.sup.15COR.sup.15, NR.sup.15SO.sub.2R.sup.16, CO.sub.2R.sup.15, COSR.sup.16, CON(R.sup.15).sub.2 and (C.sub.1-C.sub.4)-alkoxy-(C.sub.2-C.sub.6)-alkoxycarbonyl, and where heterocyclyl bears n oxo groups, R.sup.14 is acetoxy, acetamido, N-methylacetamido, benzoyloxy, benzamido, N-methylbenzamido, methoxycarbonyl, ethoxycarbonyl, benzoyl, methylcarbonyl, piperidinylcarbonyl, morpholinylcarbonyl, trifluoromethylcarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, (C.sub.3-C.sub.6)-alkoxy, (C.sub.3-C.sub.6)-cycloalkyl, or heteroaryl, heterocyclyl or phenyl, each substituted by s radicals selected from the group consisting of methyl, ethyl, methoxy, trifluoromethyl and halogen; R.sup.15 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-cycloalkyl or (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, R.sup.16 is (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl or (C.sub.2-C.sub.6)-alkynyl, R.sup.17 is (C.sub.1-C.sub.6)-alkyl, halo-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy or halo-(C.sub.1-C.sub.6)-alkoxy, s is 0, 1, 2 or 3, n is 0, 1 or 2, D is O, S, or NR.sup.11, with the proviso that V, W, X, Y and Z are not simultaneously hydrogen.

2. The acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- or N-(triazol-5-yl)arylcarboxamide of formula (I) and/or a salt as claimed in claim 1, wherein R is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-halocycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkyl-S(O).sub.nR.sup.2, (C.sub.1-C.sub.6)-alkyl-OR.sup.1, (C.sub.1-C.sub.6)-alkyl-OCOR.sup.1, (C.sub.1-C.sub.6)-alkyl-OSO.sub.2R.sup.2, (C.sub.1-C.sub.6)-alkyl-COOR.sup.1, (C.sub.1-C.sub.6)-alkyl-C(O)R.sup.1, (C.sub.1-C.sub.6)-alkyl-CN, (C.sub.1-C.sub.6)-alkyl-SO.sub.2OR.sup.1, (C.sub.1-C.sub.6)-alkyl-CON(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-SO.sub.2N(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-NR.sup.1COR.sup.1, (C.sub.1-C.sub.6)-alkyl-NR.sup.1SO.sub.2R.sup.2, COOR.sup.1, CON(R.sup.1).sub.2, or phenyl, heteroaryl, heterocyclyl or benzyl, each substituted by s radicals selected from the group consisting of X, Y, Z and V, W is N or CY, X and Z are each independently hydrogen, halogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-halocycloalkyl, OR.sup.1, S(O).sub.nR.sup.2, SO.sub.2N(R.sup.1).sub.2, NR.sup.1SO.sub.2R.sup.2, NR.sup.1COR.sup.1, (C.sub.1-C.sub.6)-alkyl-S(O).sub.nR.sup.2, (C.sub.1-C.sub.6)-alkyl-OR.sup.1, or heteroaryl, heterocyclyl or phenyl, each substituted by s radicals selected from the group of methyl, ethyl, methoxy, nitro, trifluoromethyl and halogen, Y is hydrogen, (C.sub.2-C.sub.6)-alkenyl, COR.sup.1, CO.sub.2R.sup.1, OCO.sub.2R.sup.1, NR.sup.1CO.sub.2R.sup.1, C(O)N(R.sup.1).sub.2, NR.sup.1C(O)N(R.sup.1).sub.2, OC(O)N(R.sup.1).sub.2, C(O)N(R.sup.1)OR.sup.1, NR.sup.1SO.sub.2R.sup.2, NR.sup.1COR.sup.1, OR.sup.1, S(O).sub.nR.sup.2, SO.sub.2N(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-S(O).sub.nR.sup.2, (C.sub.1-C.sub.6)-alkyl-OR.sup.1, (C.sub.1-C.sub.6)-alkyl-OCOR.sup.1, (C.sub.1-C.sub.6)-alkyl-CO.sub.2R.sup.1, (C.sub.1-C.sub.6)-alkyl-CON(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-SO.sub.2N(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-NR.sup.1COR.sup.1, (C.sub.1-C.sub.6)-alkyl-NR.sup.1SO.sub.2R.sup.2, N(R.sup.1).sub.2, CHNOR.sup.1, (C.sub.1-C.sub.6)-alkyl-CHNOR.sup.1, (C.sub.1-C.sub.6)-alkylheteroaryl, (C.sub.1-C.sub.6)-alkylheterocyclyl, heteroaryl or heterocyclyl, where the 4 latter radicals are each substituted by s radicals selected from the group consisting of halogen, nitro, cyano, (C.sub.1-C.sub.6)-alkyl, halo-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl, S(O).sub.n(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy, halo-(C.sub.1-C.sub.6)-alkoxy, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.4)-alkyl and cyanomethyl, and where heterocyclyl bears n oxo groups, V is hydrogen, Cl, OMe, methyl or ethyl, R.sup.1 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkenyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.1-C.sub.6)-alkyl-O(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, phenyl, phenyl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, (C.sub.1-C.sub.6)-alkylheteroaryl, heterocyclyl, (C.sub.1-C.sub.6)-alkylheterocyclyl, (C.sub.1-C.sub.6)-alkyl-O-heteroaryl, (C.sub.1-C.sub.6)-alkyl-O-heterocyclyl, (C.sub.1-C.sub.6)-alkyl-NR.sup.3-heteroaryl or (C.sub.1-C.sub.6)-alkyl-NR.sup.3-heterocyclyl, where the 21 latter radicals are substituted by s radicals selected from the group consisting of cyano, halogen, nitro, thiocyanato, OR.sup.3, S(O).sub.nR.sup.4, N(R.sup.3).sub.2, NR.sup.3OR.sup.3, COR.sup.3, OCOR.sup.3, SCOR.sup.4, NR.sup.3COR.sup.3, NR.sup.3SO.sub.2R.sup.4, CO.sub.2R.sup.3, COSR.sup.4, CON(R.sup.3).sub.2 and (C.sub.1-C.sub.4)-alkoxy-(C.sub.2-C.sub.6)-alkoxycarbonyl, and where heterocyclyl bears n oxo groups, R.sup.2 is (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkenyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.1-C.sub.6)-alkyl-O(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, phenyl, phenyl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, (C.sub.1-C.sub.6)-alkylheteroaryl, heterocyclyl, (C.sub.1-C.sub.6)-alkylheterocyclyl, (C.sub.1-C.sub.6)-alkyl-O-heteroaryl, (C.sub.1-C.sub.6)-alkyl-O-heterocyclyl, (C.sub.1-C.sub.6)-alkyl-NR.sup.3-heteroaryl, (C.sub.1-C.sub.6)-alkyl-NR.sup.3-heterocyclyl, where the 21 latter radicals are substituted by s radicals selected from the group consisting of cyano, halogen, nitro, thiocyanato, OR.sup.3, S(O).sub.nR.sup.4, N(R.sup.3).sub.2, NR.sup.3OR.sup.3, COR.sup.3, OCOR.sup.3, SCOR.sup.4, NR.sup.3COR.sup.3, NR.sup.3SO.sub.2R.sup.4, CO.sub.2R.sup.3, COSR.sup.4, CON(R.sup.3).sub.2 and (C.sub.1-C.sub.4)-alkoxy-(C.sub.2-C.sub.6)-alkoxycarbonyl, and where heterocyclyl bears n oxo groups, R.sup.3 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-cycloalkyl or (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, R.sup.4 is (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl or (C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-cycloalkyl or (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, n is 0, 1 or 2, s is 0, 1, 2 or 3, Q is a Q1, Q2, Q3 or Q4 radical ##STR00024## R.sup.6 and R.sup.7 are independently (C.sub.1-C.sub.6)-alkyl, halo-(C.sub.1-C.sub.6)-alkyl, or (C.sub.2-C.sub.6)-alkenyl, where these 3 aforementioned radicals are each substituted by s (C.sub.1-C.sub.6)-alkoxy radicals, R.sup.8 is chlorine, methyl, methoxymethyl, amino or acetylamino, R.sup.9 is methyl, ethyl, methoxymethyl or methoxyethyl.

3. The acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- or N-(triazol-5-yl)arylcarboxamide of the formula (I) as claimed in claim 1, wherein R is methyl, or phenyl substituted in each case by s radicals selected from the group consisting of X, Y and Z, W is CY, X is F, Cl, Br, methyl, ethyl, cyclopropyl, trifluoromethyl, methoxy, methoxymethyl, methoxyethoxymethyl, SMe or SO.sub.2Me, Z is hydrogen, F, Cl, Br, I, methyl, ethyl, trifluoromethyl, difluoromethyl, pentafluoroethyl, methylsulfonyl or ethylsulfonyl, Y is hydrogen, SMe, S(O)Me, SO.sub.2Me, SEt, S(O)Et, SO.sub.2Et, CH.sub.2OMe, CH.sub.2OEt, CH.sub.2OCH.sub.2CF.sub.3, CH.sub.2SMe, CH.sub.2S(O)Me, CH.sub.2SO.sub.2Me, vinyl, C(O)Me, C(O)Et, C(O)cPr, CO.sub.2Me, CHNOMe, 4,5-dihydro-1,2-oxazol-3-yl, 5-methyl-4,5-dihydro-1,2-oxazol-3-yl, 5-methyl-4,5-dihydro-1,2-oxazol-3-yl, 5-cyanomethyl-4,5-dihydro-1,2-oxazol-3-yl, 4,5-dihydro-1,2-oxazol-5-yl, 3-methyl-4,5-dihydro-1,2-oxazol-5-yl, 1H-pyrazol-1-yl, 1H-1,2,3-triazol-1-yl, 2H-1,2,3-triazol-2-yl, 1H-1,2,4-triazol-1-yl, pyrolidin-2-on-1-yl, morpholin-3-on-4-yl, OMe, OEt, OnPr, OCH.sub.2cPr, OCH.sub.2CH.sub.2F; OCH.sub.2CH.sub.2OMe or OCH.sub.2CH.sub.2CH.sub.2OMe, V is hydrogen, Q is a Q1, Q2, Q3 or Q4 radical ##STR00025## R.sup.6 is methyl or ethyl, R.sup.7 is methyl, R.sup.8 is chlorine or methyl, R.sup.9 is methyl, s is 0, 1, 2 or 3.

4. The acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- or N-(triazol-5-yl)arylcarboxamide of the formula (I) as claimed in claim 1, wherein Q is Q1, ##STR00026##

5. The acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- or N-(triazol-5-yl)arylcarboxamide of the formula (I) as claimed in claim 1, wherein Q is Q2, ##STR00027##

6. The acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- or N-(triazol-5-yl)arylcarboxamide of the formula (I) as claimed in claim 1, wherein Q is Q3, ##STR00028##

7. The acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- or N-(triazol-5-yl)arylcarboxamide of the formula (I) as claimed in claim 1, wherein Q is Q4, ##STR00029##

8. The acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- or N-(triazol-5-yl)arylcarboxamide of the formula (I) as claimed in claim 1, wherein W is N.

9. The acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- or N-(triazol-5-yl)arylcarboxamide of the formula (I) as claimed in claim 1, wherein W is CY, and Y is H.

10. The acylated N-(tetrazol-5-yl)arylcarboxamide of the formula (I) as claimed in claim 1, wherein the acylated N-(tetrazol-5-yl)arylcarboxamide is ##STR00030##

11. A herbicidal composition, comprising a herbicidally active content of at least one acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- or N-(triazol-5-yl)-aryl carboxamide and/or salt as claimed in claim 1.

12. The herbicidal composition as claimed in claim 11 in a mixture with one or more formulation auxiliaries.

13. The herbicidal composition as claimed in claim 12, comprising a further herbicide.

14. A method of controlling one or more unwanted plants, comprising applying an effective amount of at least one acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- or N-(triazol-5-yl)arylcarboxamide of formula (I) and/or salt as claimed in claim 1 or a herbicidal composition thereof to the plants or to a site of unwanted vegetation.

15. The method as claimed in claim 14, wherein the one or more unwanted plants are in one or more crops of useful plants.

16. The method as claimed in claim 15, wherein the useful plants are transgenic useful plants.

17. A product comprising the acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- or N-(triazol-5-yl)arylcarboxamide of formula (I) and/or salt as claimed in claim 1 or a herbicidal composition thereof for controlling one or more unwanted plants.

Description

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT

(1) Preference is given to compounds of the general formula (I) in which

(2) R is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-halocycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkyl-S(O).sub.nR.sup.2, (C.sub.1-C.sub.6)-alkyl-OR.sup.1, (C.sub.1-C.sub.6)-alkyl-OCOR.sup.1, (C.sub.1-C.sub.6)-alkyl-OSO.sub.2R.sup.2, (C.sub.1-C.sub.6)-alkyl-COOR.sup.1, (C.sub.1-C.sub.6)-alkyl-C(O)R.sup.1, (C.sub.1-C.sub.6)-alkyl-CN, (C.sub.1-C.sub.6)-alkyl-SO.sub.2OR.sup.1, (C.sub.1-C.sub.6)-alkyl-CON(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-SO.sub.2N(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-NR.sup.1COR.sup.1, (C.sub.1-C.sub.6)-alkyl-NR.sup.1SO.sub.2R.sup.2, COOR.sup.1, CON(R.sup.1).sub.2, or phenyl, heteroaryl, heterocyclyl or benzyl, each substituted by s radicals from the group consisting of X, Y, Z and V,

(3) W is N or CY,

(4) X and Z are each independently hydrogen, halogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-halocycloalkyl, OR.sup.1, S(O).sub.nR.sup.2, SO.sub.2N(R.sup.1).sub.2, NR.sup.1SO.sub.2R.sup.2, NR.sup.1COR.sup.1, (C.sub.1-C.sub.6)-alkyl-S(O).sub.nR.sup.2, (C.sub.1-C.sub.6)-alkyl-OR.sup.1, or heteroaryl, heterocyclyl or phenyl, each substituted by s radicals from the group of methyl, ethyl, methoxy, nitro, trifluoromethyl and halogen,

(5) Y is hydrogen, (C.sub.2-C.sub.6)-alkenyl, COR.sup.1, CO.sub.2R.sup.1, OCO.sub.2R.sup.1, NR.sup.1CO.sub.2R.sup.1, C(O)N(R.sup.1).sub.2, NR.sup.1C(O)N(R.sup.1).sub.2, OC(O)N(R.sup.1).sub.2, C(O)N(R.sup.1)OR.sup.1, NR.sup.1SO.sub.2R.sup.2, NR.sup.1COR.sup.1, OR.sup.1, S(O).sub.nR.sup.2, SO.sub.2N(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-S(O).sub.nR.sup.2, (C.sub.1-C.sub.6)-alkyl-OR.sup.1, (C.sub.1-C.sub.6)-alkyl-OCOR.sup.1, (C.sub.1-C.sub.6)-alkyl-CO.sub.2R.sup.1, (C.sub.1-C.sub.6)-alkyl-CON(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-SO.sub.2N(R.sup.1).sub.2, (C.sub.1-C.sub.6)-alkyl-NR.sup.1COR.sup.1, (C.sub.1-C.sub.6)-alkyl-NR.sup.1SO.sub.2R.sup.2, N(R.sup.1).sub.2, CHNOR.sup.1, (C.sub.1-C.sub.6)-alkyl-CHNOR.sup.1, (C.sub.1-C.sub.6)-alkylheteroaryl, (C.sub.1-C.sub.6)-alkylheterocyclyl, heteroaryl or heterocyclyl, where the 4 latter radicals are each substituted by s radicals from the group consisting of halogen, nitro, cyano, (C.sub.1-C.sub.6)-alkyl, halo-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl, S(O).sub.n(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy, halo-(C.sub.1-C.sub.6)-alkoxy, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.4)-alkyl and cyanomethyl, and where heterocyclyl bears n oxo groups,

(6) V is hydrogen, Cl, OMe, methyl or ethyl,

(7) R.sup.1 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkenyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.1-C.sub.6)-alkyl-O(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, phenyl, phenyl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, (C.sub.1-C.sub.6)-alkylheteroaryl, heterocyclyl, (C.sub.1-C.sub.6)-alkylheterocyclyl, (C.sub.1-C.sub.6)-alkyl-O-heteroaryl, (C.sub.1-C.sub.6)-alkyl-O-heterocyclyl, (C.sub.1-C.sub.6)-alkyl-NR.sup.3-heteroaryl or (C.sub.1-C.sub.6)-alkyl-NR.sup.3-heterocyclyl, where the 21 latter radicals are substituted by s radicals from the group consisting of cyano, halogen, nitro, thiocyanato, OR.sup.3, S(O).sub.nR.sup.4, N(R.sup.3).sub.2, NR.sup.3OR.sup.3, COR.sup.3, OCOR.sup.3, SCOR.sup.4, NR.sup.3COR.sup.3, NR.sup.3SO.sub.2R.sup.4, CO.sub.2R.sup.3, COSR.sup.4, CON(R.sup.3).sub.2 and (C.sub.1-C.sub.4)-alkoxy-(C.sub.2-C.sub.6)-alkoxycarbonyl, and where heterocyclyl bears n oxo groups,

(8) R.sup.2 is (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkenyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.1-C.sub.6)-alkyl-O(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, phenyl, phenyl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, (C.sub.1-C.sub.6)-alkylheteroaryl, heterocyclyl, (C.sub.1-C.sub.6)-alkylheterocyclyl, (C.sub.1-C.sub.6)-alkyl-O-heteroaryl, (C.sub.1-C.sub.6)-alkyl-O-heterocyclyl, (C.sub.1-C.sub.6)-alkyl-NR.sup.3-heteroaryl, (C.sub.1-C.sub.6)-alkyl-NR.sup.3-heterocyclyl, where the 21 latter radicals are substituted by s radicals from the group consisting of cyano, halogen, nitro, thiocyanato, OR.sup.3, S(O).sub.nR.sup.4, N(R.sup.3).sub.2, NR.sup.3OR.sup.3, COR.sup.3, OCOR.sup.3, SCOR.sup.4, NR.sup.3COR.sup.3, NR.sup.3SO.sub.2R.sup.4, CO.sub.2R.sup.3, COSR.sup.4, CON(R.sup.3).sub.2 and (C.sub.1-C.sub.4)-alkoxy-(C.sub.2-C.sub.6)-alkoxycarbonyl, and where heterocyclyl bears n oxo groups,

(9) R.sup.3 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-cycloalkyl or (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl,

(10) R.sup.4 is (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl or (C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.6)-cycloalkyl or (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl,

(11) n is 0, 1 or 2,

(12) s is 0, 1, 2 or 3,

(13) Q is a Q1, Q2, Q3 or Q4 radical

(14) ##STR00004##

(15) R.sup.6 and R.sup.7 are independently (C.sub.1-C.sub.6)-alkyl, halo-(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, where these 3 aforementioned radicals are each substituted by s (C.sub.1-C.sub.6)-alkoxy radicals,

(16) R.sup.8 is chlorine, methyl, methoxymethyl, amino or acetylamino,

(17) R.sup.9 is methyl, ethyl, methoxymethyl or methoxyethyl, with the proviso that V, W, X, Y and Z are not simultaneously hydrogen.

(18) Particular preference is given to compounds of the general formula (I) in which R is methyl, or phenyl substituted in each case by s radicals from the group consisting of X, Y and Z,

(19) W is CY,

(20) X is F, C.sub.1, Br, methyl, ethyl, cyclopropyl, trifluoromethyl, methoxy, methoxymethyl, methoxyethoxymethyl, SMe or SO.sub.2Me,

(21) Z is hydrogen, F, C.sub.1, Br, I, methyl, ethyl, trifluoromethyl, difluoromethyl, pentafluoroethyl, methylsulfonyl or ethylsulfonyl,

(22) Y is hydrogen, SMe, S(O)Me, SO.sub.2Me, SEt, S(O)Et, SO.sub.2Et, CH.sub.2OMe, CH.sub.2OEt, CH.sub.2OCH.sub.2CF.sub.3, CH.sub.2SMe, CH.sub.2S(O)Me, CH.sub.2SO.sub.2Me, vinyl, C(O)Me, C(O)Et, C(O)cPr, CO.sub.2Me, CHNOMe, 4,5-dihydro-1,2-oxazol-3-yl, 5-methyl-4,5-dihydro-1,2-oxazol-3-yl, 5-methyl-4,5-dihydro-1,2-oxazol-3-yl, 5-cyanomethyl-4,5-dihydro-1,2-oxazol-3-yl, 4,5-dihydro-1,2-oxazol-5-yl, 3-methyl-4,5-dihydro-1,2-oxazol-5-yl, 1H-pyrazol-1-yl, 1H-1,2,3-triazol-1-yl, 2H-1,2,3-triazol-2-yl, 1H-1,2,4-triazol-1-yl, pyrolidin-2-on-1-yl, morpholin-3-on-4-yl, OMe, OEt, OnPr, OCH.sub.2cPr, OCH.sub.2CH.sub.2F; OCH.sub.2CH.sub.2OMe or OCH.sub.2CH.sub.2CH.sub.2OMe,

(23) V is hydrogen,

(24) Q is a Q1, Q2, Q3 or Q4 radical

(25) ##STR00005##

(26) R.sup.6 is methyl or ethyl,

(27) R.sup.7 is methyl,

(28) R.sup.8 is chlorine or methyl,

(29) R.sup.9 is methyl,

(30) s is 0, 1, 2 or 3.

(31) In the formula (I) and all the formulae which follow, alkyl radicals having more than two carbon atoms may be straight-chain or branched. Alkyl radicals are, for example, methyl, ethyl, n-propyl or isopropyl, n-, iso-, t- or 2-butyl, pentyls, hexyls such as n-hexyl, isohexyl and 1,3-dimethylbutyl. Analogously, alkenyl is, for example, allyl, 1-methylprop-2-en-1-yl, 2-methylprop-2-en-1-yl, but-2-en-1-yl, but-3-en-1-yl, 1-methylbut-3-en-1-yl and 1-methylbut-2-en-1-yl. Alkynyl is, for example, propargyl, but-2-yn-1-yl, but-3-yn-1-yl, 1-methylbut-3-yn-1-yl. The multiple bond may be in any position in each unsaturated radical. Cycloalkyl is a carbocyclic saturated ring system having three to six carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Analogously, cycloalkenyl is a monocyclic alkenyl group having three to six carbon ring members, for example cyclopropenyl, cyclobutenyl, cyclopentenyl and cyclohexenyl, where the double bond may be in any position.

(32) Halogen is fluorine, chlorine, bromine or iodine.

(33) Heterocyclyl is a saturated, partly saturated or fully unsaturated cyclic radical which contains 3 to 6 ring atoms, of which 1 to 4 are from the group of oxygen, nitrogen and sulfur, and which may additionally be fused by a benzo ring. For example, heterocyclyl is piperidinyl, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl and oxetanyl.

(34) Heteroaryl is an aromatic cyclic radical which contains 3 to 6 ring atoms, of which 1 to 4 are from the group of oxygen, nitrogen and sulfur, and which may additionally be fused by a benzo ring. For example, heteroaryl is benzimidazol-2-yl, furanyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyridinyl, benzisoxazolyl, thiazolyl, pyrrolyl, pyrazolyl, thiophenyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, 2H-1,2,3,4-tetrazolyl, 1H-1,2,3,4-tetrazolyl, 1,2,3,4-oxatriazolyl, 1,2,3,5-oxatriazolyl, 1,2,3,4-thiatriazolyl and 1,2,3,5-thiatriazolyl.

(35) If a group is polysubstituted by radicals, this should be understood to mean that this group is substituted by one or more identical or different radicals selected from the radicals mentioned. The same applies to the formation of ring systems by different atoms and elements. At the same time, the scope of the claims shall exclude those compounds known by the person skilled in the art to be chemically unstable under standard conditions.

(36) Depending on the nature of the substituents and the manner in which they are attached, the compounds of the general formula (I) may be present as stereoisomers. If, for example, one or more asymmetric carbon atoms are present, enantiomers and diastereomers may occur. Stereoisomers likewise occur when n is 1 (sulfoxides). Stereoisomers can be obtained from the mixtures obtained in the preparation by customary separation methods, for example by chromatographic separation processes. It is likewise possible to selectively prepare stereoisomers by using stereoselective reactions with use of optically active starting materials and/or auxiliaries. The invention also relates to all the stereoisomers and mixtures thereof that are encompassed by the general formula (I) but are not defined specifically. Owing to the oxime ether structure, the compounds of the invention may also occur as geometric isomers (E/Z isomers). The invention also relates to all the E/Z isomers and mixtures thereof that are encompassed by the general formula (I) but are not defined specifically.

(37) The compounds of the formula (I) are capable of forming salts. Salts can be formed by the action of a base on those compounds of the formula (I) which bear an acidic hydrogen atom, for example in the case that R.sup.1 contains a COOH group or a sulfonamide group NHSO.sub.2. Examples of suitable bases are organic amines such as trialkylamines, morpholine, piperidine or pyridine, and the hydroxides, carbonates and hydrogencarbonates of ammonium, alkali metals or alkaline earth metals, especially sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate and potassium hydrogencarbonate. These salts are compounds in which the acidic hydrogen is replaced by an agriculturally suitable cation, for example metal salts, especially alkali metal salts or alkaline earth metal salts, especially sodium and potassium salts, or else ammonium salts, salts with organic amines or quaternary ammonium salts, for example with cations of the formula [NRRRR].sup.+ in which R to R are each independently an organic radical, especially alkyl, aryl, aralkyl or alkylaryl. Also suitable are alkylsulfonium and alkylsulfoxonium salts, such as (C.sub.1-C.sub.4)-trialkylsulfonium and (C.sub.1-C.sub.4)-trialkylsulfoxonium salts.

(38) The compounds of the formula (I) can form salts by addition of a suitable inorganic or organic acid, for example mineral acids, for example HCl, HBr, H.sub.2SO.sub.4, H.sub.3PO.sub.4 or HNO.sub.3, or organic acids, for example carboxylic acids such as formic acid, acetic acid, propionic acid, oxalic acid, lactic acid or salicylic acid or sulfonic acids, for example p-toluenesulfonic acid, onto a basic group, for example amino, alkylamino, dialkylamino, piperidino, morpholino or pyridino. In such a case, these salts will comprise the conjugate base of the acid as the anion.

(39) Inventive compounds can be prepared, for example, by the method specified in scheme 1, by reacting arylcarboxamide (II) with an acid chloride or an anhydride of the general formula (III):

(40) ##STR00006##

(41) The arylcarboxamides of the formula (II) are known in principle and can be prepared, for example, by the methods described in WO2011/035874 A1, WO2012/123416 A1, WO 2012/028579 A1 and WO2012/126932.

(42) Inventive compounds having two identical acyl radicals can also be prepared, for example, by the method specified in scheme 2, by reacting an amine of the formula (IV) with an acid chloride (V):

(43) ##STR00007##

(44) Inventive compounds having two identical acyl radicals can also be prepared by the method specified in scheme 3, by reacting an amine of the formula (IV) with an acid of the formula (VI):

(45) ##STR00008##

(46) For the activation, it is possible to use dehydrating reagents which are typically for amidation reactions, for example 1,1-carbonyldiimidazole (CDI), dicyclohexylcarbodiimide (DCC), 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (T3P), etc.

(47) The benzoyl chlorides of the formula (V) or their parent benzoic acids of the formula (VI) are known in principle and can be prepared, for example, by the methods described in U.S. Pat. No. 6,376,429 B1, EP 1 585 742 A1 and EP 1 202 978 A1.

(48) Collections of compounds of the formula (I) which can be synthesized by the abovementioned reactions can also be prepared in a parallelized manner, in which case this may be accomplished in a manual, partly automated or fully automated manner. It is possible, for example, to automate the conduct of the reaction, the workup or the purification of the products and/or intermediates. Overall, this is understood to mean a procedure as described, for example, by D. Tiebes in Combinatorial ChemistrySynthesis, Analysis, Screening (editor: Gnther Jung), Wiley, 1999, on pages 1 to 34.

(49) For the parallelized conduct of the reaction and workup, it is possible to use a number of commercially available instruments, for example Calypso reaction blocks from Barnstead International, Dubuque, Iowa 52004-0797, USA or reaction stations from Radleys, Shirehill, Saffron Walden, Essex, CB11 3AZ, England, or MuItiPROBE Automated Workstations from Perkin Elmer, Waltham, Mass. 02451, USA. For the parallelized purification of compounds of the general formula (I) or of intermediates which occur in the course of preparation, available apparatuses include chromatography apparatuses, for example from ISCO, Inc., 4700 Superior Street, Lincoln, Nebr. 68504, USA.

(50) The apparatuses detailed lead to a modular procedure in which the individual working steps are automated, but manual operations have to be carried out between the working steps. This can be circumvented by using partly or fully integrated automation systems in which the respective automation modules are operated, for example, by robots. Automation systems of this type can be obtained, for example, from Caliper, Hopkinton, Mass. 01748, USA.

(51) The implementation of single or multiple synthesis steps can be supported by the use of polymer-supported reagents/scavenger resins. The specialist literature describes a series of experimental protocols, for example in ChemFiles, Vol. 4, No. 1, Polymer-Supported Scavengers and Reagents for Solution-Phase Synthesis (Sigma-Aldrich).

(52) Besides the methods described herein, the preparation of compounds of the general formula (I) can take place completely or partially by solid-phase-supported methods. For this purpose, individual intermediates or all intermediates in the synthesis or a synthesis adapted for the corresponding procedure are bound to a synthesis resin. Solid-phase-supported synthesis methods are described adequately in the technical literature, for example Barry A. Bunin in The Combinatorial Index, Academic Press, 1998 and Combinatorial ChemistrySynthesis, Analysis, Screening (editor: Gnther Jung), Wiley, 1999. The use of solid-phase-supported synthesis methods permits a number of protocols, which are known from the literature and which for their part may be performed manually or in an automated manner. The reactions can be performed, for example, by means of IRORI technology in microreactors from Nexus Biosystems, 12140 Community Road, Poway, Calif. 92064, USA.

(53) Both in the solid and in the liquid phase, the implementation of individual or several synthesis steps may be supported by the use of microwave technology. The specialist literature describes a series of experimental protocols, for example in Microwaves in Organic and Medicinal Chemistry (editor: C. O. Kappe and A. Stadler), Wiley, 2005.

(54) The preparation by the processes described herein gives compounds of the formula (I) in the form of substance collections, which are called libraries. The present invention also provides libraries comprising at least two compounds of the formula (I).

(55) The inventive compounds of the formula (I), referred to hereinbelow as compounds of the invention, have an excellent herbicidal effectiveness against a broad spectrum of economically important mono- and dicotyledonous annual harmful plants. The active ingredients also have good control over perennial harmful plants which are difficult to control and produce shoots from rhizomes, root stocks or other perennial organs.

(56) The present invention therefore also provides a method for controlling unwanted plants or for regulating the growth of plants, preferably in plant crops, in which one or more compound(s) of the invention is/are applied to the plants (for example harmful plants such as monocotyledonous or dicotyledonous weeds or unwanted crop plants), the seed (for example grains, seeds or vegetative propagules such as tubers or shoot parts with buds) or the area on which the plants grow (for example the area under cultivation). The compounds of the invention can be deployed, for example, prior to sowing (if appropriate also by incorporation into the soil), prior to emergence or after emergence. Specific examples of some representatives of the monocotyledonous and dicotyledonous weed flora which can be controlled by the compounds of the invention are as follows, though the enumeration is not intended to impose a restriction to particular species.

(57) Monocotyledonous harmful plants of the genera: Aegilops, Agropyron, Agrostis, Alopecurus, Apera, Avena, Brachiaria, Bromus, Cenchrus, Commelina, Cynodon, Cyperus, Dactyloctenium, Digitaria, Echinochloa, Eleocharis, Eleusine, Eragrostis, Eriochloa, Festuca, Fimbristylis, Heteranthera, Imperata, Ischaemum, Leptochloa, Lolium, Monochoria, Panicum, Paspalum, Phalaris, Phleum, Poa, Rottboellia, Sagittaria, Scirpus, Setaria, Sorghum.

(58) Dicotyledonous weeds of the genera: Abutilon, Amaranthus, Ambrosia, Anoda, Anthemis, Aphanes, Artemisia, Atriplex, Bellis, Bidens, Capsella, Carduus, Cassia, Centaurea, Chenopodium, Cirsium, Convolvulus, Datura, Desmodium, Emex, Erysimum, Euphorbia, Galeopsis, Galinsoga, Galium, Hibiscus, Ipomoea, Kochia, Lamium, Lepidium, Lindernia, Matricaria, Mentha, Mercurialis, Mullugo, Myosotis, Papaver, Pharbitis, Plantago, Polygonum, Portulaca, Ranunculus, Raphanus, Rorippa, Rotala, Rumex, Salsola, Senecio, Sesbania, Sida, Sinapis, Solanum, Sonchus, Sphenoclea, Stellaria, Taraxacum, Thlaspi, Trifolium, Urtica, Veronica, Viola, Xanthium.

(59) If the compounds of the invention are applied to the soil surface before germination, either the emergence of the weed seedlings is prevented completely or the weeds grow until they have reached the cotyledon stage, but then they stop growing and ultimately die completely after three to four weeks have passed.

(60) If the active ingredients are applied post-emergence to the green parts of the plants, growth stops after the treatment, and the harmful plants remain at the growth stage of the point of time of application, or they die completely after a certain time, so that in this manner competition by the weeds, which is harmful to the crop plants, is eliminated very early and in a sustained manner.

(61) Although the compounds of the invention have outstanding herbicidal activity against monocotyledonous and dicotyledonous weeds, crop plants of economically important crops, for example dicotyledonous crops of the genera Arachis, Beta, Brassica, Cucumis, Cucurbita, Helianthus, Daucus, Glycine, Gossypium, Ipomoea, Lactuca, Linum, Lycopersicon, Nicotiana, Phaseolus, Pisum, Solanum, Vicia, or monocotyledonous crops of the genera Allium, Ananas, Asparagus, Avena, Hordeum, Oryza, Panicum, Saccharum, Secale, Sorghum, Triticale, Triticum, Zea, in particular Zea and Triticum, will be damaged to a negligible extent only, if at all, depending on the structure of the particular compound of the invention and its application rate. For these reasons, the present compounds are very suitable for selective control of unwanted plant growth in plant crops such as agriculturally useful plants or ornamental plants.

(62) In addition, the compounds of the invention (depending on their particular structure and the application rate deployed) have outstanding growth-regulating properties in crop plants. They intervene in the plants' own metabolism with regulatory effect, and can thus be used for the controlled influencing of plant constituents and to facilitate harvesting, for example by triggering desiccation and stunted growth. Furthermore, they are also suitable for the general control and inhibition of unwanted vegetative growth without killing the plants in the process. Inhibition of vegetative growth plays a major role for many mono- and dicotyledonous crops since, for example, this can reduce or completely prevent lodging.

(63) By virtue of their herbicidal and plant growth regulatory properties, the active ingredients can also be used to control harmful plants in crops of genetically modified plants or plants modified by conventional mutagenesis. In general, the transgenic plants are characterized by particular advantageous properties, for example by resistances to certain pesticides, in particular certain herbicides, resistances to plant diseases or pathogens of plant diseases, such as certain insects or microorganisms such as fungi, bacteria or viruses. Other particular properties relate, for example, to the harvested material with regard to quantity, quality, storability, composition and specific constituents. For instance, there are known transgenic plants with an elevated starch content or altered starch quality, or those with a different fatty acid composition in the harvested material.

(64) It is preferable, with respect to transgenic crops, to use the compounds of the invention in economically important transgenic crops of useful plants and ornamentals, for example of cereals such as wheat, barley, rye, oats, millet/sorghum, rice and corn or else crops of sugar beet, cotton, soybean, oilseed rape, potato, tomato, peas and other types of vegetable. Preferably, the compounds of the invention can be used as herbicides in crops of useful plants which are resistant, or have been made resistant by genetic engineering, to the phytotoxic effects of the herbicides.

(65) It is preferred to use the compounds of the invention in economically important transgenic crops of useful plants and ornamentals, for example of cereals such as wheat, barley, rye, oats, millet/sorghum, rice, cassava and corn or else crops of sugar beet, cotton, soybean, oilseed rape, potato, tomato, peas and other types other vegetable. Preferably, the compounds of the invention can be used as herbicides in crops of useful plants which are resistant, or have been made resistant by genetic engineering, to the phytotoxic effects of the herbicides.

(66) Conventional ways of producing novel plants which have modified properties in comparison to existing plants consist, for example, in traditional cultivation methods and the generation of mutants. Alternatively, novel plants with modified properties can be generated with the aid of recombinant methods (see, for example, EP-A-0221044, EP-A-0131624). For example, there have been descriptions in several cases of: genetic modifications of crop plants for the purpose of modifying the starch synthesized in the plants (e.g. WO 92/11376, WO 92/14827, WO 91/19806), transgenic crop plants which are resistant to particular herbicides of the glufosinate type (cf., for example, EP-A-0242236, EP-A-242246) or glyphosate type (WO 92/00377) or the sulfonylurea type (EP-A-0257993, U.S. Pat. No. 5,013,659), transgenic crop plants, for example cotton, capable of producing Bacillus thuringiensis toxins (Bt toxins), which make the plants resistant to particular pests (EP-A-0142924, EP-A-0193259), transgenic crop plants with a modified fatty acid composition (WO 91/13972), genetically modified crop plants with novel constituents or secondary metabolites, for example novel phytoalexins, which bring about an increased disease resistance (EPA 309862, EPA0464461), genetically modified plants having reduced photorespiration, which have higher yields and higher stress tolerance (EPA 0305398), transgenic crop plants which produce pharmaceutically or diagnostically important proteins (molecular pharming), transgenic crop plants which feature higher yields or better quality, transgenic crop plants which feature, for example, the abovementioned novel properties (gene stacking) through combinations.

(67) Numerous molecular biology techniques which can be used to produce novel transgenic plants with modified properties are known in principle; see, for example, I. Potrykus and G. Spangenberg (eds.) Gene Transfer to Plants, Springer Lab Manual (1995), Springer Verlag Berlin, Heidelberg, or Christou, Trends in Plant Science 1 (1996) 423-431).

(68) For such recombinant manipulations, nucleic acid molecules which allow mutagenesis or sequence alteration by recombination of DNA sequences can be introduced into plasmids. With the aid of standard methods, it is possible, for example, to undertake base exchanges, remove parts of sequences or add natural or synthetic sequences. To join the DNA fragments with one another, adapters or linkers can be placed onto the fragments, see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2nd edition Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., or Winnacker Gene and Klone [Genes and clones], VCH Weinheim 2nd edition 1996.

(69) For example, the generation of plant cells with a reduced activity of a gene product can be achieved by expressing at least one corresponding antisense RNA, a sense RNA for achieving a cosuppression effect, or by expressing at least one suitably constructed ribozyme which specifically cleaves transcripts of the abovementioned gene product. To this end, it is firstly possible to use DNA molecules which encompass the entire coding sequence of a gene product inclusive of any flanking sequences which may be present, and also DNA molecules which only encompass portions of the coding sequence, in which case it is necessary for these portions to be long enough to have an antisense effect in the cells. It is also possible to use DNA sequences which have a high degree of homology to the coding sequences of a gene product, but are not completely identical to them.

(70) When expressing nucleic acid molecules in plants, the protein synthesized may be localized in any desired compartment of the plant cell. However, to achieve localization in a particular compartment, it is possible, for example, to join the coding region to DNA sequences which ensure localization in a particular compartment. Such sequences are known to those skilled in the art (see, for example, Braun et al., EMBO J. 11 (1992), 3219-3227, Wolter et al., Proc. Natl. Acad. Sci. USA 85 (1988), 846-850; Sonnewald et al., Plant J. 1 (1991), 95-106). The nucleic acid molecules can also be expressed in the organelles of the plant cells.

(71) The transgenic plant cells can be regenerated by known techniques to give rise to entire plants. In principle, the transgenic plants may be plants of any desired plant species, i.e. not only monocotyledonous but also dicotyledonous plants.

(72) Thus, transgenic plants can be obtained whose properties are altered by overexpression, suppression or inhibition of homologous (=natural) genes or gene sequences or expression of heterologous (=foreign) genes or gene sequences.

(73) The compounds of the invention can be used with preference in transgenic crops which are resistant to growth regulators, for example dicamba, or to herbicides which inhibit essential plant enzymes, for example acetolactate synthases (ALS), EPSP synthases, glutamine synthases (GS) or hydroxyphenylpyruvate dioxygenases (HPPD), or to herbicides from the group of the sulfonylureas, the glyphosates, glufosinates or benzoylisoxazoles and analogous active ingredients.

(74) When the active ingredients of the invention are employed in transgenic crops, not only do the effects toward harmful plants observed in other crops occur, but frequently also effects which are specific to application in the particular transgenic crop, for example an altered or specifically widened spectrum of weeds which can be controlled, altered application rates which can be used for the application, preferably good combinability with the herbicides to which the transgenic crop is resistant, and influencing of growth and yield of the transgenic crop plants.

(75) The invention therefore also provides for the use of the compounds of the invention as herbicides for control of harmful plants in transgenic crop plants.

(76) The compounds of the invention can be applied in the form of wettable powders, emulsifiable concentrates, sprayable solutions, dusting products or granules in the customary formulations. The invention therefore also provides herbicidal and plant-growth-regulating compositions which comprise the compounds of the invention.

(77) The compounds of the invention can be formulated in various ways, according to the biological and/or physicochemical parameters required. Possible formulations include, for example: wettable powders (WP), water-soluble powders (SP), water-soluble concentrates, emulsifiable concentrates (EC), emulsions (EW), such as oil-in-water and water-in-oil emulsions, sprayable solutions, suspension concentrates (SC), dispersions based on oil or water, oil-miscible solutions, capsule suspensions (CS), dusting products (DP), dressings, granules for scattering and soil application, granules (GR) in the form of microgranules, spray granules, absorption and adsorption granules, water-dispersible granules (WG), water-soluble granules (SG), ULV formulations, microcapsules and waxes.

(78) These individual formulation types are known in principle and are described, for example, in: Winnacker-Kchler, Chemische Technologie [Chemical Technology], volume 7, C. Hanser Verlag Munich, 4th Ed. 1986, Wade van Valkenburg, Pesticide Formulations, Marcel Dekker, N.Y., 1973, K. Martens, Spray Drying Handbook, 3rd Ed. 1979, G. Goodwin Ltd. London.

(79) The formulation auxiliaries required, such as inert materials, surfactants, solvents and further additives, are likewise known and are described, for example, in: Watkins, Handbook of Insecticide Dust Diluents and Carriers, 2nd Ed., Darland Books, Caldwell N.J.; H. v. Olphen, Introduction to Clay Colloid Chemistry, 2nd Ed., J. Wiley & Sons, N.Y.; C. Marsden, Solvents Guide, 2nd Ed., Interscience, N.Y. 1963; McCutcheon's Detergents and Emulsifiers Annual, MC Publ. Corp., Ridgewood N.J.; Sisley and Wood, Encyclopedia of Surface Active Agents, Chem. Publ. Co. Inc., N.Y. 1964; Schnfeldt, Grenzflchenaktive thylenoxidaddukte [Interface-active Ethylene Oxide Adducts], Wiss. Verlagsgesellschaft, Stuttgart 1976; Winnacker-Kchler, Chemische Technologie [Chemical Engineering], volume 7, C. Hanser Verlag Munich, 4th Ed. 1986.

(80) On the basis of these formulations, it is also possible to produce combinations with other pesticidally active substances, for example insecticides, acaricides, herbicides, fungicides, and also with safeners, fertilizers and/or growth regulators, for example in the form of a finished formulation or as a tankmix. Suitable safeners are, for example, mefenpyr-diethyl, cyprosulfamide, isoxadifen-ethyl, cloquintocet-mexyl and dichlormid.

(81) Wettable powders are preparations which can be dispersed uniformly in water and, in addition to the active ingredient, apart from a diluent or inert substance, also comprise surfactants of the ionic and/or nonionic type (wetting agents, dispersants), for example polyoxyethylated alkylphenols, polyoxyethylated fatty alcohols, polyoxyethylated fatty amines, fatty alcohol polyglycol ether sulfates, alkanesulfonates, alkylbenzenesulfonates, sodium lignosulfonate, sodium 2,2-dinaphthylmethane-6,6-disulfonate, sodium dibutylnaphthalenesulfonate or else sodium oleoylmethyltaurate. To produce the wettable powders, the active herbicidal ingredients are finely ground, for example in customary apparatuses such as hammer mills, blower mills and air-jet mills, and simultaneously or subsequently mixed with the formulation auxiliaries.

(82) Emulsifiable concentrates are produced by dissolving the active ingredient in an organic solvent, for example butanol, cyclohexanone, dimethylformamide, xylene, or else relatively high-boiling aromatics or hydrocarbons or mixtures of the organic solvents, with addition of one or more ionic and/or nonionic surfactants (emulsifiers).

(83) Examples of emulsifiers which may be used are: calcium alkylarylsulfonates such as calcium dodecylbenzenesulfonate, or nonionic emulsifiers such as fatty acid polyglycol esters, alkylaryl polyglycol ethers, fatty alcohol polyglycol ethers, propylene oxide-ethylene oxide condensation products, alkyl polyethers, sorbitan esters, for example sorbitan fatty acid esters, or polyoxyethylene sorbitan esters, for example polyoxyethylene sorbitan fatty acid esters.

(84) Dusting products are obtained by grinding the active ingredient with finely distributed solids, for example talc, natural clays, such as kaolin, bentonite and pyrophyllite, or diatomaceous earth.

(85) Suspension concentrates may be water- or oil-based. They may be prepared, for example, by wet-grinding by means of commercial bead mills and optional addition of surfactants as have, for example, already been listed above for the other formulation types.

(86) Emulsions, for example oil-in-water emulsions (EW), can be produced, for example, by means of stirrers, colloid mills and/or static mixers using aqueous organic solvents and optionally surfactants as already listed above, for example, for the other formulation types.

(87) Granules can be produced either by spraying the active ingredient onto adsorptive granular inert material or by applying active ingredient concentrates to the surface of carriers, such as sand, kaolinites or granular inert material, by means of adhesives, for example polyvinyl alcohol, sodium polyacrylate or else mineral oils. Suitable active ingredients can also be granulated in the manner customary for the production of fertilizer granulesif desired as a mixture with fertilizers.

(88) Water-dispersible granules are produced generally by the customary processes such as spray-drying, fluidized-bed granulation, pan granulation, mixing with high-speed mixers and extrusion without solid inert material.

(89) For the production of pan, fluidized-bed, extruder and spray granules, see e.g. processes in Spray-Drying Handbook 3rd Ed. 1979, G. Goodwin Ltd., London, J. E. Browning, Agglomeration, Chemical and Engineering 1967, pages 147 ff.; Perry's Chemical Engineer's Handbook, 5th Ed., McGraw-Hill, New York 1973, pp. 8-57.

(90) For further details regarding the formulation of crop protection compositions, see, for example, G. C. Klingman, Weed Control as a Science, John Wiley and Sons, Inc., New York, 1961, pages 81-96 and J. D. Freyer, S. A. Evans, Weed Control Handbook, 5th Ed., Blackwell Scientific Publications, Oxford, 1968, pages 101-103.

(91) The agrochemical preparations contain generally 0.1 to 99% by weight, especially 0.1 to 95% by weight, of compounds of the invention.

(92) In wettable powders, the active ingredient concentration is, for example, about 10 to 90% by weight, the remainder to 100% by weight consisting of customary formulation constituents. In emulsifiable concentrates, the active ingredient concentration may be about 1% to 90% and preferably 5% to 80% by weight. Dust-type formulations contain 1% to 30% by weight of active ingredient, preferably usually 5% to 20% by weight of active ingredient; sprayable solutions contain about 0.05% to 80% by weight, preferably 2% to 50% by weight of active ingredient. In the case of water-dispersible granules, the active ingredient content depends partially on whether the active compound is in liquid or solid form and on which granulation auxiliaries, fillers, etc., are used. In the water-dispersible granules, the content of active ingredient is, for example, between 1% and 95% by weight, preferably between 10% and 80% by weight.

(93) In addition, the active ingredient formulations mentioned optionally comprise the respective customary stickers, wetters, dispersants, emulsifiers, penetrants, preservatives, antifreeze agents and solvents, fillers, carriers and dyes, defoamers, evaporation inhibitors and agents which influence the pH and the viscosity.

(94) For application, the formulations in commercial form are, if appropriate, diluted in a customary manner, for example in the case of wettable powders, emulsifiable concentrates, dispersions and water-dispersible granules with water. Dust-type preparations, granules for soil application or granules for scattering and sprayable solutions are not normally diluted further with other inert substances prior to application.

(95) The required application rate of the compounds of the formula (I) varies with the external conditions, including, inter alia, temperature, humidity and the type of herbicide used. It can vary within wide limits, for example between 0.001 and 1.0 kg/ha or more of active substance, but it is preferably between 0.005 and 750 g/ha.

(96) The examples which follow illustrate the invention.

A. Chemical Examples

1. Synthesis of 2-(methylsulfonyl)-4-trifluoromethyl-N-acetyl-N-(1-methyltetrazol-5-yl)benzamide (Table Example No. 13-1)

(97) To 175 mg (0.5 mmol) of 2-(methylsulfonyl)-4-trifluoromethyl-N-(1-methyltetrazol-5-yl)benzamide in 5 ml of THF under argon at 0 C. are added 14 mg (0.55 mmol) of sodium hydride (95%). After stirring for 10 min, 47 mg (0.6 mmol) of acetyl chloride are added. The mixture is stirred at 0 C. for 1 h and then quenched with 2 mL of saturated sodium bicarbonate solution. The mixture is diluted with ethyl acetate and water, and the organic phase is washed with saturated sodium bicarbonate solution and sodium chloride solution, dried over Na2SO4 and concentrated. Yield 143 mg (73%).

2. Synthesis of 3-(ethoxycarbonyl)-2-methyl-4-(methylsulfanyl)-N-(3-(ethoxycarbonyl)-2-methyl-4-(methylsulfanyl)benzoyl)-N-(1-methyltetrazol-5-yl)benzamide (Table Example No. 1-453)

(98) To 525 mg (2.06 mmol) of 3-(ethoxycarbonyl)-2-methyl-4-(methylsulfanyl)benzoic acid, 313 mg (3.09 mmol) of 1-methyl-5-aminotetrazole in 3 ml of pyridine are added, while cooling with an ice bath, 367 mg (3.09 mmol) of thionyl chloride. The mixture is stirred at RT for 3 days, then 0.2 mL of water is added, the mixture is stirred at RT for 30 min, and EA and 2 N HCl are added. The organic phase removed is washed once again with 2 N HCl and saturated sodium chloride solution, dried over Na2SO4, concentrated and purified by means of RP-HPLC (acetonitrile/water). Yield 112 mg (9%). An additional 58 mg (11% yield) of 3-(ethoxycarbonyl)-2-methyl-4-(methylsulfanyl)-N-(1-methyltetrazol-5-yl)benzamide were obtained.

(99) The examples listed in the tables below were prepared analogously to the abovementioned methods or are obtainable analogously to the abovementioned methods. The compounds listed in the tables below are very particularly preferred.

(100) The abbreviations used mean:

(101) Et=ethyl Me=methyl n-Pr=n-propyl i-Pr=isopropyl c-Pr=cyclopropyl Ph=phenyl

(102) TABLE-US-00001 TABLE 1 Inventive compounds of the formula (I) in which Q is Q1, W is CY, R is substituted phenyl and R.sup.6 is methyl. embedded image Physical data No. X Y Z V (.sup.1H-NMR, DMSO-d.sub.6, 400 MHz) 1-1 F H Cl H 1-2 F H SO.sub.2Me H 1-3 F H SO.sub.2Et H 1-4 F H CF.sub.3 H 1-5 F H NO.sub.2 H 1-6 Cl H Br H 1-7 Cl H SMe H 1-8 Cl H SOMe H 1-9 Cl H SO.sub.2Me H 1-10 Cl H SO.sub.2CH.sub.2Cl H 1-11 Cl H SEt H 1-12 Cl H SO.sub.2Et H 1-13 Cl H CF.sub.3 H 1-14 Cl H NO.sub.2 H 1-15 Cl H pyrazol-1-yl H 1-16 Cl H 1H-1,2,4- H triazol-1-yl 1-17 Br H Cl H 1-18 Br H Br H 1-19 Br H SO.sub.2Me H 1-20 Br H SO.sub.2Et H 1-21 Br H CF.sub.3 H 1-22 SO.sub.2Me H Cl H 1-23 SO.sub.2Me H Br H 1-24 SO.sub.2Me H SMe H 1-25 SO.sub.2Me H SOMe H 1-26 SO.sub.2Me H SO.sub.2Me H 1-27 SO.sub.2Me H SO.sub.2Et H 1-28 SO.sub.2Me H CF.sub.3 H 8.38 (s, 2H), 8.30 (d, 2H), 8.21 (brs, 2H), 4.20 (s, 3H), 3.41 (s, 6H), 2.22 (s, 3H) 1-29 SO.sub.2Et H Cl H 1-30 SO.sub.2Et H Br H 1-31 SO.sub.2Et H SMe H 1-32 SO.sub.2Et H SOMe H 1-33 SO.sub.2Et H SO.sub.2Me H 1-34 SO.sub.2Et H CF.sub.3 H 1-35 NO.sub.2 H F H 1-36 NO.sub.2 H Cl H 1-37 NO.sub.2 H Br H 1-38 NO.sub.2 H I H 1-39 NO.sub.2 H CN H 1-40 NO.sub.2 H SO.sub.2Me H 1-41 NO.sub.2 H SO.sub.2Et H 1-42 NO.sub.2 H CF.sub.3 H 1-43 Me H Cl H 1-44 Me H Br H 1-45 Me H SMe H 1-46 Me H SO.sub.2Me H 1-47 Me H SO.sub.2CH.sub.2Cl H 1-48 Me H SEt H 1-49 Me H SO.sub.2Et H 1-50 Me H CF.sub.3 H 1-51 CH.sub.2SO.sub.2Me H CF.sub.3 H 1-52 Et H Cl H 1-53 Et H Br H 1-54 Et H SMe H 1-55 Et H SO.sub.2Me H 1-56 Et H SO.sub.2CH.sub.2Cl H 1-57 Et H SEt H 1-58 Et H SO.sub.2Et H 1-59 Et H CF.sub.3 H 1-60 CF.sub.3 H Cl H 1-61 CF.sub.3 H Br H 1-62 CF.sub.3 H SO.sub.2Me H 1-63 CF.sub.3 H SO.sub.2Et H 1-64 CF.sub.3 H CF.sub.3 H 1-65 NO.sub.2 NH.sub.2 F H 1-66 NO.sub.2 NHMe F H 1-67 NO.sub.2 NMe.sub.2 F H 1-68 NO.sub.2 Me Cl H 1-69 NO.sub.2 NH.sub.2 Cl H 1-70 NO.sub.2 NHMe Cl H 1-71 NO.sub.2 NMe.sub.2 Cl H 1-72 NO.sub.2 NH.sub.2 Br H 1-73 NO.sub.2 NHMe Br H 1-74 NO.sub.2 NMe.sub.2 Br H 1-75 NO.sub.2 NH.sub.2 CF.sub.3 H 1-76 NO.sub.2 NMe.sub.2 CF.sub.3 H 1-77 NO.sub.2 NH.sub.2 SO.sub.2Me H 1-78 NO.sub.2 NH.sub.2 SO.sub.2Et H 1-79 NO.sub.2 NHMe SO.sub.2Me H 1-80 NO.sub.2 NMe.sub.2 SO.sub.2Me H 1-81 NO.sub.2 NMe.sub.2 SO.sub.2Et H 1-82 NO.sub.2 NH.sub.2 1H-1,2,4- H triazol-1-yl 1-83 NO.sub.2 NHMe 1H-1,2,4- H triazol-1-yl 1-84 NO.sub.2 NMe.sub.2 1H-1,2,4- H triazol-1-yl 1-85 Me SMe H H .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 7.518 (0.8); 7.325 (1.0); 7.320 (1.2); 7.310 (0.4); 7.306 (2.3); 7.301 (2.3); 7.280 (2.0); 7.272 (0.3); 7.2694 (0.4); 7.2687 (0.4); 7.268 (0.5); 7.266 (0.7); 7.265 (0.9); 7.259 (133.8); 7.242 (1.8); 7.170 (1.5); 7.166 (1.6); 7.150 (1.1); 7.146 (1.1); 6.995 (0.7); 5.298 (1.0); 4.107 (9.8); 2.446 (16.0); 1.527 (33.0); 0.008 (1.6) 1-86 Me SOMe H H 8.10-8.06 (m, 2H), 7.69-7.60 (m, 4H), 4.10 (s, 3H), 2.79 (s, 6H), 1-87 Me SO.sub.2Me H H 1-88 Me SEt H H 1-89 Me SOEt H H 1-90 Me SO.sub.2Et H H 1-91 Me S(CH.sub.2).sub.2OMe H H 1-92 Me SO(CH.sub.2).sub.2OMe H H 1-93 Me SO.sub.2(CH.sub.2).sub.2OMe H H 1-94 Me F F H 1-95 Me F SMe H 1-96 Me SEt F H 1-97 Me SOEt F H 1-98 Me SO.sub.2Et F H 1-99 Me Me Cl H 1-100 Me F Cl H 1-101 Me Cl Cl H 1-102 Me NH.sub.2 Cl H 1-103 Me NHMe Cl H 1-104 Me NMe.sub.2 Cl H 1-105 Me O(CH.sub.2).sub.2OMe Cl H 1-106 Me O(CH.sub.2).sub.3OMe Cl H 1-107 Me O(CH.sub.2).sub.4OMe Cl H 1-108 Me OCH.sub.2CONMe.sub.2 Cl H 1-109 Me O(CH.sub.2).sub.2CONMe.sub.2 Cl H 1-110 Me O(CH.sub.2).sub.2NH(CO)NMe.sub.2 Cl H 1-111 Me O(CH.sub.2).sub.2NH(CO)NHCO.sub.2Et Cl H 1-112 Me O(CH.sub.2).sub.2NHCO.sub.2Me Cl H 1-113 Me OCH.sub.2NHSO.sub.2cPr Cl H 1-114 Me O(CH.sub.2)-5-2,4- Cl H dimethyl-2,4- dihydro-3H-1,2,4- triazol-3-one 1-115 Me O(CH.sub.2)-3,5- Cl H dimethyl-1,2-oxazol- 4-yl 1-116 Me SMe Cl H 1-117 Me SOMe Cl H 1-118 Me SO.sub.2Me Cl H 1-119 Me SEt Cl H 1-120 Me SOEt Cl H 1-121 Me SO.sub.2Et Cl H 1-122 Me S(CH.sub.2).sub.2OMe Cl H 1-123 Me SO(CH.sub.2).sub.2OMe Cl H 1-124 Me SO.sub.2(CH.sub.2).sub.2OMe Cl H 1-125 Me NH.sub.2 Br H 1-126 Me NHMe Br H 1-127 Me NMe.sub.2 Br H 1-128 Me OCH.sub.2(CO)NMe.sub.2 Br H 1-129 Me O(CH.sub.2)-5-pyrrolidin- Br H 2-one 1-130 Me SMe Br H 1-131 Me SOMe Br H 1-132 Me SO.sub.2Me Br H 1-133 Me SEt Br H 1-134 Me SOEt Br H 1-135 Me SO.sub.2Et Br H 1-136 Me SMe I H 1-137 Me SOMe I H 1-138 Me SO.sub.2Me I H 1-139 Me SEt I H 1-140 Me SOEt I H 1-141 Me SO.sub.2Et I H 1-142 Me Cl CF.sub.3 H 1-143 Me SMe CF.sub.3 H 1-144 Me SOMe CF.sub.3 H 1-145 Me SO.sub.2Me CF.sub.3 H 1-146 Me SEt CF.sub.3 H 1-147 Me SOEt CF.sub.3 H 1-148 Me SO.sub.2Et CF.sub.3 H 1-149 Me S(CH.sub.2).sub.2OMe CF.sub.3 H 1-150 Me SO.sub.2(CH.sub.2).sub.2OMe CF.sub.3 H 1-151 Me SO.sub.2(CH.sub.2).sub.2OMe CF.sub.3 H 1-152 Me Me SO.sub.2Me H 1-153 Me 4,5-dihydro-1,2- SO.sub.2Me H oxazol-3-yl 1-154 Me 4,5-dihydro-1,2- SO.sub.2Et H oxazol-3-yl 1-155 Me 5-cyanomethyl-4,5- SO.sub.2Me H dihydro-1,2-oxazol- 3-yl 1-156 Me 5-cyanomethyl-4,5- SO.sub.2Et H dihydro-1,2-oxazol- 3-yl 1-157 Me NH.sub.2 SO.sub.2Me H 1-158 Me NHMe SO.sub.2Me H 1-159 Me NMe.sub.2 SO.sub.2Me H 1-160 Me NH(CH.sub.2).sub.2OMe SO.sub.2Me H 1-161 Me pyrazol-1-yl SO.sub.2Me H 1-162 Me OH SO.sub.2Me H 1-163 Me OMe SO.sub.2Me H 1-164 Me OMe SO.sub.2Et H 1-165 Me OEt SO.sub.2Me H 1-166 Me OEt SO.sub.2Et H 1-167 Me O-i-Pr SO.sub.2Me H 1-168 Me O-i-Pr SO.sub.2Et H 1-169 Me O(CH.sub.2).sub.2OMe SO.sub.2Me H 1-170 Me O(CH.sub.2).sub.2OMe SO.sub.2Et H 1-171 Me O(CH.sub.2).sub.3OMe SO.sub.2Me H 1-172 Me O(CH.sub.2).sub.3OMe SO.sub.2Et H 1-173 Me O(CH.sub.2).sub.4OMe SO.sub.2Me H 1-174 Me O(CH.sub.2).sub.4OMe SO.sub.2Et H 1-175 Me O(CH.sub.2).sub.2NHSO2Me SO.sub.2Me H 1-176 Me O(CH.sub.2).sub.2NHSO2Me SO.sub.2Et H 1-177 Me OCH.sub.2(CO)NMe.sub.2 SO.sub.2Me H 1-178 Me OCH.sub.2(CO)NMe.sub.2 SO.sub.2Et H 1-179 Me [1,4]dioxan-2- SO.sub.2Me H ylmethoxy 1-180 Me [1,4]dioxan-2- SO.sub.2Et H ylmethoxy 1-181 Me O(CH.sub.2).sub.2O-(3,5-di SO.sub.2Me H methoxypyrimidin-2- yl) 1-182 Me Cl SO.sub.2Me H 1-183 Me SMe SO.sub.2Me H 1-184 Me SOMe SO.sub.2Me H 1-185 Me SO.sub.2Me SO.sub.2Me H 1-186 Me SO.sub.2Me SO.sub.2Et H 1-187 Me SEt SO.sub.2Me H 1-188 Me SOEt SO.sub.2Me H 1-189 Me SO.sub.2Et SO.sub.2Me H 1-190 Me S(CH.sub.2).sub.2OMe SO.sub.2Me H 1-191 Me SO(CH.sub.2).sub.2OMe SO.sub.2Me H 1-192 Me SO.sub.2(CH.sub.2).sub.2OMe SO2Me H 1-193 CH.sub.2SMe OMe SO.sub.2Me H 1-194 CH.sub.2OMe OMe SO.sub.2Me H 1-195 CH.sub.2O(CH.sub.2).sub.2OMe NH(CH.sub.2).sub.2OEt SO.sub.2Me H 1-196 CH.sub.2O(CH.sub.2).sub.2OMe NH(CH.sub.2).sub.3OEt SO.sub.2Me H 1-197 CH.sub.2O(CH.sub.2).sub.3OMe OMe SO.sub.2Me H 1-198 CH.sub.2O(CH.sub.2).sub.2OMe NH(CH.sub.2).sub.2OMe SO.sub.2Me H 1-199 CH.sub.2O(CH.sub.2).sub.2OMe NH(CH.sub.2).sub.3OMe SO.sub.2Me H 1-200 Et SMe Cl H 1-201 Et SO.sub.2Me Cl H 1-202 Et SMe CF.sub.3 H 1-203 Et SO.sub.2Me CF.sub.3 H 1-204 Et F SO.sub.2Me H 1-205 Et NH(CH.sub.2).sub.2OMe SO.sub.2Me H 1-206 i-Pr SO.sub.2Me CF.sub.3 H .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 7.821 (1.6); 7.801 (1.9); 7.593 (0.8); 7.575 (0.7); 7.263 (18.6); 7.260 (18.8); 5.301 (6.9); 5.298 (7.1); 4.312 (0.3); 4.295 (0.8); 4.277 (1.1); 4.260 (0.8); 4.242 (0.4); 4.133 (0.4); 4.131 (0.5); 4.120 (8.4); 4.117 (8.5); 3.335 (15.8); 3.334 (16.0); 3.266 (1.0); 3.264 (1.0); 3.196 (0.8); 3.194 (0.8); 2.046 (1.5); 2.044 (1.5); 1.714 (0.4); 1.643 (0.4); 1.640 (0.5); 1.625 (0.4); 1.623 (0.4); 1.521 (12.5); 1.503 (12.3); 1.395 (0.5); 1.393 (0.5); 1.378 (0.4); 1.375 (0.4); 1.294 (0.5); 1.292 (0.5); 1.279 (0.6); 1.277 (0.9); 1.262 (1.0); 1.259 (1.1); 1.244 (0.4); 1.241 (0.5); 0.003 (8.2); 0.000 (8.9) 1-207 cPr SO.sub.2Me CF.sub.3 H 1-208 CF.sub.3 O(CH.sub.2).sub.2OMe F H 1-209 CF.sub.3 O(CH.sub.2).sub.3OMe F H 1-210 CF.sub.3 OCH.sub.2CONMe.sub.2 F H 1-211 CF.sub.3 [1,4]dioxan-2- F H ylmethoxy 1-212 CF.sub.3 O(CH.sub.2).sub.2OMe Cl H 1-213 CF.sub.3 O(CH.sub.2).sub.3OMe Cl H 1-214 CF.sub.3 OCH.sub.2CONMe.sub.2 Cl H 1-215 CF.sub.3 [1,4]dioxan-2- Cl H ylmethoxy 1-216 CF.sub.3 O(CH.sub.2).sub.2OMe Br H 1-217 CF.sub.3 O(CH.sub.2).sub.3OMe Br H 1-218 CF.sub.3 OCH.sub.2CONMe.sub.2 Br H 1-219 CF.sub.3 [1,4]dioxan-2- Br H ylmethoxy 1-220 CF.sub.3 O(CH.sub.2).sub.2OMe I H 1-221 CF.sub.3 O(CH.sub.2).sub.3OMe I H 1-222 CF.sub.3 OCH.sub.2CONMe.sub.2 I H 1-223 CF.sub.3 [1,4]dioxan-2- I H ylmethoxy 1-224 CF.sub.3 F SO.sub.2Me H 1-225 CF.sub.3 F SO.sub.2Et H 1-226 CF.sub.3 O(CH.sub.2).sub.2OMe SO.sub.2Me H 1-227 CF.sub.3 O(CH.sub.2).sub.2OMe SO.sub.2Et H 1-228 CF.sub.3 O(CH.sub.2).sub.3OMe SO.sub.2Me H 1-229 CF.sub.3 O(CH.sub.2).sub.3OMe SO.sub.2Et H 1-230 CF.sub.3 OCH.sub.2CONMe.sub.2 SO.sub.2Me H 1-231 CF.sub.3 OCH.sub.2CONMe.sub.2 SO.sub.2Et H 1-232 CF.sub.3 [1,4]dioxan-2- SO.sub.2Me H ylmethoxy 1-233 CF.sub.3 [1,4]dioxan-2- SO.sub.2Et H ylmethoxy 1-234 F SMe CF.sub.3 H 1-235 F SOMe CF.sub.3 H 1-236 Cl Me Cl H 1-237 Cl OCH.sub.2CHCH.sub.2 Cl H 1-238 Cl OCH.sub.2CHF.sub.2 Cl H 1-239 Cl O(CH.sub.2).sub.2OMe Cl H 1-240 Cl OCH.sub.2CONMe.sub.2 Cl H 1-241 Cl O(CH.sub.2)-5-pyrrolidin- Cl H 2-one 1-242 Cl SMe Cl H 1-243 Cl SOMe Cl H 1-244 Cl SO.sub.2Me Cl H 1-245 Cl F SMe H 1-246 Cl Cl SO.sub.2Me H 1-247 Cl CO.sub.2Me SO.sub.2Me H 1-248 Cl CONMe.sub.2 SO.sub.2Me H 1-249 Cl CONMe(OMe) SO.sub.2Me H 1-250 Cl CH.sub.2OMe SO.sub.2Me H 1-251 Cl CH.sub.2OMe SO.sub.2Et H 1-252 Cl CH.sub.2OEt SO.sub.2Me H 1-253 Cl CH.sub.2OEt SO.sub.2Et H 1-254 Cl CH.sub.2OCH.sub.2CHF.sub.2 SO.sub.2Me H 1-255 Cl CH.sub.2OCH.sub.2CF.sub.3 SO.sub.2Me H 1-256 Cl CH.sub.2OCH.sub.2CF.sub.3 SO.sub.2Et H 1-257 Cl CH.sub.2OCH.sub.2CF.sub.2CHF.sub.2 SO.sub.2Me H 1-258 Cl CH.sub.2OcPentyl SO.sub.2Me H 1-259 Cl CH.sub.2PO(OMe).sub.2 SO.sub.2Me H 1-260 Cl 4,5-dihydro-1,2- SMe H oxazol-3-yl 1-261 Cl 4,5-dihydro-1,2- SO.sub.2Me H oxazol-3-yl 1-262 Cl 4,5-dihydro-1,2- SO.sub.2Et H oxazol-3-yl 1-263 Cl 5-cyanomethyl-4,5- SO.sub.2Me H dihydro-1,2-oxazol- 3-yl 1-264 Cl 5-cyanomethyl-4,5- SO.sub.2Et H dihydro-1,2-oxazol- 3-yl 1-265 Cl 5-(methoxymethyl)- SO.sub.2Et H 4,5-dihydro-1,2- oxazol-3-yl 1-266 Cl 5-(methoxymethyl)- SO.sub.2Et H 5-methyl-4,5- dihydro-1,2-oxazol- 3-yl 1-267 Cl CH.sub.2O- SO.sub.2Me H tetrahydrofuran-3-yl 1-268 Cl CH.sub.2O- SO.sub.2Et tetrahydrofuran-3-yl 1-269 Cl CH.sub.2OCH.sub.2- SO.sub.2Me H tetrahydrofuran-2-yl 1-270 Cl CH.sub.2OCH.sub.2- SO.sub.2Et H tetrahydrofuran-2-yl 1-271 Cl CH.sub.2OCH.sub.2- SO.sub.2Me H tetrahydrofuran-3-yl 1-272 Cl CH.sub.2OCH.sub.2- SO.sub.2Et H tetrahydrofuran-3-yl 1-273 Cl OMe SO.sub.2Me H 1-274 Cl OMe SO.sub.2Et H 1-275 Cl OEt SO.sub.2Me H 1-276 Cl OEt SO.sub.2Et H 1-277 Cl O-i-Pr SO.sub.2Me H 1-278 Cl O-i-Pr SO.sub.2Et H 1-279 Cl O(CH.sub.2).sub.2OMe SO.sub.2Me H 1-280 Cl O(CH.sub.2).sub.4OMe SO.sub.2Me H 1-281 Cl O(CH.sub.2).sub.4OMe SO.sub.2Et H 1-282 Cl O(CH.sub.2).sub.3OMe SO.sub.2Me H 1-283 Cl O(CH.sub.2).sub.3OMe SO.sub.2Et H 1-284 Cl O(CH.sub.2).sub.2OMe SO.sub.2Me H 1-285 Cl O(CH.sub.2).sub.2OMe SO.sub.2Et H 1-286 Cl [1,4]dioxan-2- SO.sub.2Me H ylmethoxy 1-287 Cl [1,4]dioxan-2- SO.sub.2Et H ylmethoxy 1-288 Cl OCH.sub.2(CO)NMe.sub.2 SO.sub.2Me H 1-289 Cl OCH.sub.2(CO)NMe.sub.2 SO.sub.2Et H 1-290 Cl SMe SO.sub.2Me H 1-291 Cl SOMe SO.sub.2Me H 1-292 Br OMe Br H 1-293 Br O(CH.sub.2).sub.2OMe Br H 1-294 Br O(CH.sub.2).sub.2OMe SO.sub.2Me H 1-295 Br O(CH.sub.2).sub.2OMe SO.sub.2Et H 1-296 Br O(CH.sub.2).sub.3OMe SO.sub.2Me H 1-297 Br O(CH.sub.2).sub.3OMe SO.sub.2Et H 1-298 Br O(CH.sub.2).sub.4OMe SO.sub.2Me H 1-299 Br O(CH.sub.2).sub.4OMe SO.sub.2Et H 1-300 Br [1,4]dioxan-2- SO.sub.2Me H ylmethoxy 1-301 Br [1,4]dioxan-2- SO.sub.2Et H ylmethoxy 1-302 I O(CH.sub.2).sub.2OMe SO.sub.2Me H 1-303 I O(CH.sub.2).sub.2OMe SO.sub.2Et H 1-304 I O(CH.sub.2).sub.3OMe SO.sub.2Me H 1-305 I O(CH.sub.2).sub.3OMe SO.sub.2Et H 1-306 I O(CH.sub.2).sub.4OMe SO.sub.2Me H 1-307 I O(CH.sub.2).sub.4OMe SO.sub.2Et H 1-308 I [1,4]dioxan-2- SO.sub.2Me H ylmethoxy 1-309 I [1,4]dioxan-2- SO.sub.2Et H ylmethoxy 1-310 OMe SMe CF.sub.3 H 1-311 OMe SOMe CF.sub.3 H 1-312 OMe SO.sub.2Me CF.sub.3 H 1-313 OMe SOEt CF.sub.3 H 1-314 OMe SO.sub.2Et CF.sub.3 H 1-315 OMe S(CH.sub.2).sub.2OMe CF.sub.3 H 1-316 OMe SO(CH.sub.2).sub.2OMe CF.sub.3 H 1-317 OMe SO.sub.2(CH.sub.2).sub.2OMe CF.sub.3 H 1-318 OMe SMe Cl H 1-319 OMe SOMe Cl H 1-320 OMe SO.sub.2Me Cl H 1-321 OMe SEt Cl H 1-322 OMe SOEt Cl H 1-323 OMe SO2Et Cl H 1-324 OMe S(CH.sub.2).sub.2OMe Cl H 1-325 OMe SO(CH.sub.2).sub.2OMe Cl H 1-326 OMe SO.sub.2(CH.sub.2).sub.2OMe Cl H 1-327 OCH.sub.2c-Pr SMe CF.sub.3 H 1-328 OCH.sub.2c-Pr SOMe CF.sub.3 H 1-329 OCH.sub.2c-Pr SO.sub.2Me CF.sub.3 H 1-330 OCH.sub.2c-Pr SEt CF.sub.3 H 1-331 OCH.sub.2c-Pr SOEt CF.sub.3 H 1-332 OCH.sub.2c-Pr SO.sub.2Et CF.sub.3 H 1-333 OCH.sub.2c-Pr S(CH.sub.2).sub.2OMe CF.sub.3 H 1-334 OCH.sub.2c-Pr SO(CH.sub.2).sub.2OMe CF.sub.3 H 1-335 OCH.sub.2c-Pr SO.sub.2(CH.sub.2).sub.2OMe CF.sub.3 H 1-336 OCH.sub.2c-Pr SMe Cl H 1-337 OCH.sub.2c-Pr SOMe Cl H 1-338 OCH.sub.2c-Pr SO.sub.2Me Cl H 1-339 OCH.sub.2c-Pr SEt Cl H 1-340 OCH.sub.2c-Pr SOEt Cl H 1-341 OCH.sub.2c-Pr SO.sub.2Et Cl H 1-342 OCH.sub.2c-Pr S(CH.sub.2).sub.2OMe Cl H 1-343 OCH.sub.2c-Pr SO(CH.sub.2).sub.2OMe Cl H 1-344 OCH.sub.2c-Pr SO.sub.2(CH.sub.2).sub.2OMe Cl H 1-345 OCH.sub.2c-Pr SMe SO.sub.2Me H 1-346 OCH.sub.2c-Pr SOMe SO.sub.2Me H 1-347 OCH.sub.2c-Pr SO.sub.2Me SO.sub.2Me H 1-348 OCH.sub.2c-Pr SEt SO.sub.2Me H 1-349 OCH.sub.2c-Pr SOEt SO.sub.2Me H 1-350 OCH.sub.2c-Pr SO.sub.2Et SO.sub.2Me H 1-351 OCH.sub.2c-Pr S(CH.sub.2).sub.2OMe SO.sub.2Me H 1-352 OCH.sub.2c-Pr SO(CH.sub.2).sub.2OMe SO.sub.2Me H 1-353 OCH.sub.2c-Pr SO.sub.2(CH.sub.2).sub.2OMe SO.sub.2Me H 1-354 SO.sub.2Me F CF.sub.3 H 1-355 SO.sub.2Me NH.sub.2 CF.sub.3 H 1-356 SO.sub.2Me NHEt Cl H 1-357 SMe SEt F H 1-358 SMe SMe F H 1-359 SMe SMe CF.sub.3 H 1-360 SMe SOMe CF.sub.3 H 1-361 SMe SO.sub.2Me CF.sub.3 H 1-362 SMe SMe Cl H 1-363 SMe SMe Br H 1-364 Cl Ac CF.sub.3 H 1-365 Cl Ac SO.sub.2Me H 1-366 Cl C(O)cPr CF.sub.3 H 1-367 Cl C(O)cPr SO.sub.2Me H 1-368 Cl CH.sub.2SMe CF.sub.3 H 1-369 Cl CH.sub.2S(O)Me CF.sub.3 H 1-370 Cl CH.sub.2SO.sub.2Me CF.sub.3 H 1-371 Cl CH.sub.2SMe SO.sub.2Me H 1-372 Cl CH.sub.2S(O)Me SO.sub.2Me H 1-373 Cl CH.sub.2SO.sub.2Me SO.sub.2Me H 1-374 Cl CHNOMe CF.sub.3 H 1-375 Cl CHNOMe SO.sub.2Me H 1-376 Cl 4,5-dihydro-1,2- CF.sub.3 H oxazol-5-yl, 1-377 Cl 4,5-dihydro-1,2- SO.sub.2Me H oxazol-5-yl, 1-378 Cl 3-methyl-4,5- CF.sub.3 H dihydro-1,2-oxazol- 5-yl 1-379 Cl 3-methyl-4,5- SO.sub.2Me H dihydro-1,2-oxazol- 5-yl 1-380 Cl vinyl CF.sub.3 H 1-381 Cl vinyl SO.sub.2Me H 1-382 Cl CO.sub.2Me CF.sub.3 H 1-383 Cl CO.sub.2Me SO.sub.2Me H 1-384 Cl SMe CF.sub.3 H 1-385 Cl S(O)Me CF.sub.3 H 1-386 Cl SO.sub.2Me CF.sub.3 H 1-387 Cl SO.sub.2Me SO.sub.2Me H 1-388 Cl SMe Me H 1-389 Cl SOMe Me H 1-390 Cl SO.sub.2Me Me H 1-391 Cl 1H-1,2,4-triazol-1-yl CF.sub.3 H 1-392 Cl 1H-1,2,3-triazol-1-yl CF.sub.3 H 1-393 Cl 2H-1,2,3-triazol-2-yl CF.sub.3 H 1-394 Cl 1H-pyrazol-1-yl CF.sub.3 H 1-395 Cl 1H-4- CF.sub.3 H chloropyrazol-1-yl 1-396 Cl 1H-3- CF.sub.3 H bromopyrazol-1-yl 1-397 Cl 1H-4- CF.sub.3 H trifluoromethyl- pyrazol-1-yl 1-398 Cl pyrolidin-2-on-1-yl CF.sub.3 H 1-399 Cl morpholin-3-on-4-yl CF.sub.3 H 1-400 Cl 1,2-thiazolidine- CF.sub.3 H 1,1-dioxid-2-yl 1-401 Br 1H-1,2,4-triazol-1-yl CF.sub.3 H 1-402 Br 1H-1,2,4-triazol-1-yl CF.sub.3 H 1-403 Br 2H-1,2,3-triazol-2-yl CF.sub.3 H 1-404 Br 1H-pyrazol-1-yl CF.sub.3 H 1-405 Br 1H-4- CF.sub.3 H chloropyrazol-1-yl 1-406 Br 1H-3- CF.sub.3 H bromopyrazol-1-yl 1-407 Br 1H-4- CF.sub.3 H trifluoromethyl- pyrazol-1-yl 1-408 Br pyrolidin-2-on-1-yl CF.sub.3 H 1-409 Br morpholin-3-on-4-yl CF.sub.3 H 1-410 Br 1,2-thiazolidine- CF.sub.3 H 1,1-dioxid-2-yl 1-411 CH.sub.2OMe 1H-1,2,4-triazol-1-yl CF.sub.3 H 1-412 CH.sub.2OMe 1H-1,2,4-triazol-1-yl CF.sub.3 H 1-413 CH.sub.2OMe 2H-1,2,3-triazol-2-yl CF.sub.3 H 1-414 CF.sub.3 OCH.sub.2CH.sub.2F CF.sub.3 H 1-415 CF.sub.3 OMe CF.sub.3 H 1-416 CF.sub.3 SMe CF.sub.3 H 1-417 CF.sub.3 SOMe CF.sub.3 H 1-418 CF.sub.3 SO.sub.2Me CF.sub.3 H 1-419 CF.sub.3 1H-pyrazol-1-yl CF.sub.3 H 1-420 Me SMe Et H 1-421 Me SOMe Et H 1-422 Me SO.sub.2Me Et H 1-423 Me 1H-pyrazol-1-yl Et H 1-424 Me OCH.sub.2CH.sub.2F Et H 1-425 Me OMe Et H 1-426 Me Ac CF.sub.3 H 1-427 Me Ac SO.sub.2Me H 1-428 Me C(O)cPr CF.sub.3 H 1-429 Me C(O)cPr SO.sub.2Me H 1-430 Me CH.sub.2SMe CF.sub.3 H 1-431 Me CH.sub.2S(O)Me CF.sub.3 H 1-432 Me CH.sub.2SO.sub.2Me CF.sub.3 H 1-433 Me CH.sub.2SMe SO.sub.2Me H 1-434 Me CH.sub.2S(O)Me SO.sub.2Me H 1-435 Me CH.sub.2SO.sub.2Me SO.sub.2Me H 1-436 Me CHNOMe CF.sub.3 H 1-437 Me CHNOMe SO.sub.2Me H 1-438 Me 4,5-dihydro-1,2- CF.sub.3 H oxazol-5-yl, 1-439 Me 4,5-dihydro-1,2- SO.sub.2Me H oxazol-5-yl, 1-440 Me 3-methyl-4,5- CF.sub.3 H dihydro-1,2-oxazol- 5-yl 1-441 Me 3-methyl-4,5- SO.sub.2Me H dihydro-1,2-oxazol- 5-yl 1-442 Me vinyl CF.sub.3 H 1-443 Me vinyl SO.sub.2Me H 1-444 Me CO.sub.2Me CF.sub.3 H 1-445 Me CO.sub.2Me SO.sub.2Me H 1-446 Me CO.sub.2Me SMe H 1-447 Me NH.sub.2 CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.519 (0.7); 7.284 (2.2); 7.260 (119.6); 6.996 (0.7); 6.821 (1.9); 6.801 (1.8); 4.281 (2.5); 4.064 (15.4); 2.422 (2.3); 2.137 (16.0); 2.045 (2.1); 1.552 (1.7); 1.277 (0.7); 1.259 (1.4); 1.241 (0.6); 0.882 (0.7); 0.008 (1.3); 0.000 (39.1); 0.009 (1.1) 1-448 Me NMe.sub.2 CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.468 (0.9); 7.448 (1.4); 7.373 (1.2); 7.353 (0.8); 7.260 (55.6); 4.087 (7.4); 2.826 (1.4); 2.684 (16.0); 2.520 (0.7); 2.291 (8.3); 1.545 (2.5); 0.008 (0.6); 0.000 (19.2); 0.009 (0.5) 1-449 Me NHMe CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.373 (1.7); 7.352 (2.0); 7.261 (33.1); 7.133 (1.7); 7.113 (1.5); 4.063 (16.0); 2.729 (10.7); 2.356 (14.5); 1.553 (1.5); 1.256 (1.2); 0.000 (12.2) 1-450 Me SO.sub.2Me Me H .sup.1H-NMR (600.1 MHz, CD.sub.3CN): 7.673 (2.0); 7.659 (2.1); 7.298 (1.7); 7.285 (1.6); 4.093 (8.5); 3.043 (16.0); 2.628 (12.0); 2.615 (12.0); 2.135 (28.1); 2.103 (0.4); 2.101 (0.5); 1.956 (0.4); 1.951 (0.7); 1.948 (3.0); 1.944 (5.3); 1.939 (7.4); 1.935 (5.1); 1.931 (2.6); 0.000 (2.7) 1-451 Me SMe Me H 1-452 Me SEt OMe H .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 7.579 (2.4); 7.558 (2.5); 7.260 (34.2); 6.694 (2.0); 6.672 (1.9); 4.027 (9.7); 3.876 (16.0); 2.720 (1.4); 2.701 (4.4); 2.683 (4.5); 2.665 (1.5); 2.549 (13.8); 1.546 (6.4); 1.256 (1.0); 1.042 (4.7); 1.023 (9.8); 1.005 (4.5) 1-453 Me CO.sub.2Et SMe H 7.86 (d, 2H), 7.24 (d, 2H), 4.32 (q, 4H), 4.16 (s, 3H), 2.49 (s, 6H), 2.25 (s, 6H), 1.31 (t, 6H) 1-454 Me SMe NMe.sub.2 H .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 7.447 (1.3); 7.426 (1.4); 7.262 (8.6); 6.766 (0.7); 6.744 (0.7); 5.298 (0.7); 4.024 (6.4); 2.852 (16.0); 2.517 (7.5); 2.131 (12.3) 1-455 Me SMe c-Pr H 7.38 (d, 2H), 6.60 (d, 2H), 4.04 (s, 3H), 2.75-2.65 (m, 2H), 2.53 (s, 6H), 2.14 (s, 6H), 1.11-1.06 (m, 4H), 0.70-0.67 (m, 4H) 1-456 Me SMe OMe H .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 7.548 (1.6); 7.526 (1.7); 7.262 (11.5); 6.699 (1.3); 6.678 (1.2); 4.029 (7.8); 3.903 (11.1); 2.542 (9.1); 2.203 (16.0) 1-457 Me SMe OEt H .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 7.506 (1.6); 7.484 (1.7); 7.266 (0.4); 7.2654 (0.5); 7.2645 (0.8); 7.261 (26.5); 7.256 (0.8); 7.2554 (0.6); 7.2546 (0.5); 7.254 (0.5); 7.253 (0.4); 7.252 (0.3); 6.665 (1.3); 6.643 (1.3); 5.299 (2.2); 4.132 (0.8); 4.124 (0.4); 4.114 (2.6); 4.108 (0.5); 4.097 (2.6); 4.079 (0.9); 4.033 (0.5); 4.027 (7.5); 3.995 (0.8); 3.788 (1.0); 2.838 (0.4); 2.511 (9.3); 2.494 (0.5); 2.322 (0.9); 2.245 (1.4); 2.240 (0.4); 2.229 (0.7); 2.228 (0.7); 2.223 (16.0); 2.193 (1.5); 2.153 (0.4); 1.526 (0.4); 1.518 (0.4); 1.509 (0.9); 1.503 (2.9); 1.494 (1.1); 1.485 (6.1); 1.477 (0.7); 1.468 (2.8); 1.258 (0.5); 1.256 (0.5); 0.000 1-458 Me SMe OCH.sub.2CF.sub.3 H .sup.1H-NMR (400.0 MHz, d.sub.6-DMSO): 7.789 (1.8); 7.767 (1.9); 7.030 (1.4); 7.008 (1.3); 4.901 (0.6); 4.880 (1.7); 4.858 (1.8); 4.836 (0.6); 4.145 (7.6); 3.321 (125.9); 3.297 (4.7); 2.706 (1.1); 2.524 (0.7); 2.519 (1.0); 2.510 (14.8); 2.506 (32.2); 2.501 (45.2); 2.497 (31.5); 2.492 (13.9); 2.427 (9.2); 2.279 (2.2); 2.169 (16.0); 0.858 (0.5); 0.000 (5.0) 1-459 Me F SMe H 1-460 Me SMe H Me .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 7.525 (0.4); 7.517 (1.5); 7.309 (1.3); 7.273 (0.6); 7.272 (0.6); 7.271 (0.7); 7.258 (264.8); 7.251 (2.7); 7.250 (2.5); 7.249 (2.2); 7.2474 (1.7); 7.2466 (1.6); 7.246 (1.4); 7.245 (1.3); 7.244 (1.1); 7.2433 (1.1); 7.2425 (1.0); 7.242 (0.9); 7.241 (0.9); 7.240 (0.8); 7.2393 (0.7); 7.2385 (0.7); 7.238 (0.6); 7.237 (0.6); 7.235 (0.5); 7.234 (0.5); 7.233 (0.4); 7.232 (0.4); 7.229 (0.4); 7.177 (0.5); 7.024 (1.7); 6.994 (1.5); 6.945 (1.7); 4.072 (10.7); 2.574 (2.3); 2.462 (4.6); 2.372 (16.0); 2.359 (2.4); 2.358 (2.4); 2.305 (7.5); 2.304 (7.8); 2.155 (8.8); 1.529 (3.4); 1.258 (1.2); 0.051 (0.4); 0.011 (0.5); 0.008 (2.7); 0.000 (86.3) 1-461 Me NO.sub.2 H Br 1-462 Et SMe Br H 1-463 Et SEt Cl H 1-464 Et SOMe CF.sub.3 H 1-465 Et SOMe Cl H 1-466 Et SEt CF.sub.3 H 1-467 Et SOEt CF.sub.3 H 1-468 Et SO.sub.2Et CF.sub.3 H 1-469 OMe CH.sub.2OMe Cl H 1-470 OMe CH.sub.2-2H-tetrazol-2- Cl H 8.50 (s, 2H), 7.59 (d, 2H), 7.30 yl (d, 2H), 6.06 (s, 2H), 4.02 (s, 3H), 3.93 (s, 6H) 1-471 OEt SMe CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.616 (1.1); 7.615 (1.1); 7.595 (2.3); 7.559 (3.3); 7.539 (1.6); 7.260 (21.7); 5.298 (1.1); 4.267 (1.1); 4.249 (3.5); 4.231 (3.6); 4.214 (1.1); 4.119 (11.8); 2.307 (16.0); 1.495 (4.7); 1.477 (10.2); 1.459 (4.5); 0.000 (7.1) 1-472 OEt SO.sub.2Me CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.897 (0.6); 7.876 (4.3); 7.870 (5.5); 7.849 (0.8); 7.520 (0.6); 7.294 (0.6); 7.268 (0.7); 7.266 (1.1); 7.261 (109.0); 6.997 (0.6); 4.237 (0.9); 4.220 (2.8); 4.202 (2.9); 4.185 (0.9); 4.154 (13.5); 3.191 (16.0); 1.566 (4.3); 1.548 (13.4); 1.531 (4.4); 4.284 (0.8); 1.259 (1.8); 0.880 (0.7); 0.008 (1.5); 0.000 (48.2); 0.009 (1.3) 1-473 Cl S-nPr CF.sub.3 H 1-474 Cl SOEt CF.sub.3 H 1-475 Cl SO.sub.2Et CF.sub.3 H 1-476 Cl Vinyl SMe H 1-477 Cl CH.sub.2OMe OMe H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.596 (2.2); 7.574 (2.3); 7.260 (50.1); 6.811 (1.7); 6.789 (1.7); 4.557 (6.1); 4.060 (7.2); 3.868 (11.6); 3.325 (16.0); 1.537 (1.9); 1.256 (0.5); 0.008 (0.6); 0.000 (18.8); 0.009 (0.6) 1-478 Cl CH.sub.2OMe SMe H 1-479 Cl C(O)-c-Pr Me H 7.47 (d, 2H), 7.17 (d, 2H), 4.09 (s, 3H), 2.26 (s, 6H), 2.12-2.07 (m, 2H), 1.32-1.29 (m, 4H), 1.15-1.10 (m, 4H) 1-480 Cl CH(OMe)-i-Pr Cl H 1-481 Cl CH.sub.2ONCH.sub.2 Cl H 1-482 Cl CH.sub.2ONCHMe Cl H 1-483 Cl CH.sub.2ONCMe.sub.2 Cl H 1-484 Cl [diethyl(oxido)- Cl H lambda.sup.6- sulfanylidene]amino 1-485 Cl (4-oxido- Cl H 1,4lambda.sup.4- oxathian-4- ylidene)amino 1-486 Cl 2-methylpyridin-3-yl Me H 1-487 Cl 3-methyl-4,5- SMe H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): dihydro-1,2-oxazol- 7.519 (2.0); 7.460 (1.8); 7.451 5-yl (1.9); 7.440 (2.8); 7.430 (2.7); 7.368 (2.1); 7.344 (2.4); 7.323 (1.6); 7.310 (0.7); 7.294 (3.5); 7.260 (390.8); 7.229 (0.6); 6.996 (2.1); 6.503 (0.8); 6.492 (0.8); 6.474 (1.7); 6.462 (1.6); 6.445 (0.8); 6.433 (0.8); 4.169 (7.9); 4.161 (7.9); 4.131 (0.7); 4.113 (0.6); 3.259 (2.4); 3.232 (2.1); 2.349 (15.7); 2.344 (15.3); 2.091 (16.0); 2.045 (2.5); 2.007 (2.1); 1.544 (10.2); 1.277 (0.7); 1.259 (1.6); 1.241 (0.8); 0.034 (1.2); 0.008 (3.9); 0.000 (123.9); 0.009 (3.5) 1-488 Cl SEt CF.sub.3 H 1-489 Cl Me F Me 7.55 (d, 2H), 4.18 (s, 3H), 2.20 (d, 6H), 2.16 (d, 6H) 1-490 Cl H F Me .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.519 (2.0); 7.460 (1.8); 7.451 (1.9); 7.440 (2.8); 7.430 (2.7); 7.368 (2.1); 7.344 (2.4); 7.323 (1.6); 7.310 (0.7); 7.294 (3.5); 7.260 (390.8); 7.229 (0.6); 6.996 (2.1); 6.503 (0.8); 6.492 (0.8); 6.474 (1.7); 6.462 (1.6); 6.445 (0.8); 6.433 (0.8); 4.169 (7.9); 4.161 (7.9); 4.131 (0.7); 4.113 (0.6); 3.259 (2.4); 3.232 (2.1); 2.349 (15.7); 2.344 (15.3); 2.091 (16.0); 2.045 (2.5); 2.007 (2.1); 1.544 (10.2); 1.277 (0.7); 1.259 (1.6); 1.241 (0.8); 0.034 (1.2); 0.008 (3.9); 0.000 (123.9); 0.009 (3.5) 1-491 Br CH.sub.2OMe SO.sub.2Me H 1-492 Br F CF.sub.3 H 1-493 Br 1H-pyazol-1-yl Cl H 1-494 I SMe H Me 1-495 CH.sub.2OMe SMe CF.sub.3 H 1-496 CH.sub.2OMe SCH.sub.2CH.sub.2OMe CF.sub.3 H 1-497 c-Pr SOMe CF.sub.3 H 1-498 c-Pr SMe Et H .sup.1H NMR (400 MHz, CDCl.sub.3): 7.260 (29.5); 7.230 (1.1); 7.210 (1.5); 7.104 (1.4); 7.084 (1.1); 4.025 (7.7); 2.960 (0.7); 2.941 (2.1); 2.922 (2.2); 2.904 (0.7); 2.322 (16.0); 2.149 (0.6); 1.535 (1.0); 1.398 (0.7); 1.224 (3.2); 1.206 (7.2); 1.187 (3.1); 1.158 (1.1); 1.154 (1.2); 1.143 (0.5); 1.137 (1.1); 1.133 (1.1); 0.949 (1.0); 0.945 (1.3); 0.934 (1.1); 0.000 (12.8) 1-499 SMe vinyl Cl H 1-500 SMe 3-methyl-4,5- Cl H dihydro-1,2-oxazol- 5-yl 1-501 SO.sub.2Me 1H-pyrazol-1-yl Cl H 8.63-8.38 (broad; 2H); 8.27 (s, broad, 2H), 8.09 (s broad, 2H), 7.89 (s broad, 2H), 6.58 (s broad, 2H), 4.17 (s, 3H), 3.31 (s, 6H); 1-502 SO.sub.2Me 1H-pyrazol-1-yl CF.sub.3 H 8.31-7.96 (broad; 4H); 7.88- 7.65 (broad, 4H), 6.55 (s broad, 2H), 4.23 (s, 3H), 3.27 (s, 6H); 1-503 SO.sub.2Me 1H-pyrazol-1-yl OMe H 8.49-7.89 (broad; 4H); 7.85- 7.39 (broad, 4H), 6.55 (s, 2H), 4.15 (s, 3H), 3.84 (s, 6H); 3.29 (s, 6H). 1-504 SO.sub.2Me 1H-pyrazol-1-yl Me H 8.09-7.73 (m; 8H); 6.58 (s, 2H), 4.16 (s, 3H), 3.31 (s, 6H); 3.08 (s, 6H). 1-505 SO.sub.2Me 1H-pyrazol-1-yl 1H-pyrazol-1-yl H

(103) TABLE-US-00002 TABLE 2 Inventive compounds of the formula (I) in which Q is Q1, W is CY, R is substituted phenyl and R.sup.6 is ethyl. Table 2 contains 454 compounds (2-1 to 2-454) in which X, Y and Z are as defined in examples 1-1 to 1-454 of table 1, and examples cited hereinafter: 0embedded image Physical data (.sup.1H-NMR, DMSO-d.sub.6, No. X Y Z V 400 MHz) 2- Me SMe H Me 7.02 (s, 2H), 6.93 (s, 2H), 460 4.33 (q, 2H), 2.35 (s, 6H), 2.30 (s, 6H), 2.14 (s, 6H), 1.68 (t, 3H) 2- Me NO.sub.2 H Br .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 461 8.292 (2.4); 8.287 (2.5); 8.106 (0.6); 8.101 (0.7); 8.039 (0.6); 8.034 (0.5); 8.017 (2.4); 8.012 (2.2); 7.259 (72.2); 4.553 (1.0); 4.535 (1.0); 3.501 (0.8); 2.610 (16.0); 2.576 (5.0); 1.684 (1.5); 1.666 (3.2); 1.647 (1.5); 0.008 (0.8); 0.000 (26.9); 0.009 (0.8) 2- Et SEt Cl H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 463 7.393 (3.5); 7.372 (6.0); 7.317 (6.6); 7.296 (3.9); 7.260 (81.7); 4.309 (1.1); 4.291 (3.5); 4.273 (3.6); 4.254 (1.1); 2.988 (1.1); 2.969 (3.6); 2.951 (3.7); 2.932 (1.2); 2.830 (2.1); 2.811 (7.1); 2793 (7.2); 2.774 (2.3); 2.044 (0.5); 1.689 (3.7); 1.671 (8.1); 1.653 (3.6); 1.551 (1.3); 1.259 (0.8); 1.256 (0.8); 1.234 (4.6); 1.216 (11.1); 1.197 (5.4); 1.195 (8.9); 1.176 (16.0); 1.158 (7.3); 0.008 (0.8); 0.000 (26.8); 0.009 (0.9) 2- Cl CH.sub.2OMe OMe H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 477 7.607 (2.1); 7.586 (2.3); 7.260 (91.8); 6.996 (0.5); 6.799 (1.6); 6.777 (1.6); 5.298 (0.7); 4.552 (5.7); 4.342 (1.5); 4.323 (1.5); 3.863 (11.0); 3.322 (16.0); 2.101 (2.1); 1.649 (1.6); 1.631 (3.5); 1.613 (1.6); 1.536 (1.5); 1.256 (0.8); 0.008 (1.1); 0.000 (35.0); 0.009 (1.0) 2- Cl CH(OMe)-i-Pr Cl H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 480 7.519 (1.0); 7.409 (3.1); 7.389 (9.0); 7.367 (5.5); 7.346 (2.0); 7.260 (190.6); 7.253 (0.8); 6.996 (1.0); 4.594 (1.3); 4.348 (1.4); 4.331 (1.4); 3.137 (6.9); 2.495 (0.6); 2.005 (0.5); 1.690 (7.1); 1.671 (15.7); 1.653 (7.1); 1.256 (0.8); 1.149 (16.0); 1.132 (15.5); 0.655 (5.0); 0.639 (5.2); 0.008 (2.3); 0.007 (0.8); 0.006 (0.9); 0.005 (1.0); 0.004 (1.4); 0.000 (66.8); 0.005 (0.7); 0.006 (0.5); 0.008 (1.7) 2- SMe vinyl Cl H .sup.1H-NMR (400.0 MHz, CDCl.sub.3); 499 7.402 (1.7); 7.381 (2.3); 7.266 (2.0); 7.260 (17.6); 7.246 (1.4); 6.846 (0.8); 6.815 (0.6); 6.803 (0.6); 6.772 (0.9); 5.754 (5.2); 5.727 (1.4); 5.724 (1.8); 5.711 (1.7); 5.708 (1.3); 4.519 (0.5); 4.500 (1.7); 4.482 (1.7); 4.464 (0.5); 2.274 (16.0); 1.672 (1.8); 1.654 (4.0); 1.636 (1.8); 1.542 (1.6); 0.0000 (6.1) 2- SMe 3-methyl-4,5- Cl H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 500 dihydro-1,2- 7.445 (1.7); 7.434 (1.9); 7.425 oxazol-5-yl (2.7); 7.413 (2.7); 7.361 (1.7); 7.340 (1.2); 7.334 (1.8); 7.313 (1.3); 7.261 (76.7); 7.228 (0.7); 6.504 (0.8); 6.488 (0.8); 6.475 (1.7); 6.459 (1.5); 6.446 (0.8); 6.430 (0.8); 4.484 (1.1); 4.470 (1.7); 4.466 (1.3); 4.451 (1.6); 3.260 (2.1); 3.258 (2.1); 3.235 (1.7); 3.227 (1.9); 2.342 (15.5); 2.336 (14.9): 2.092 (16.0); 2.045 (0.8); 1.674 (1.9); 1.670 (2.0); 1.656 (4.4); 1.652 (4.4); 1.637 (2.0); 1.633 (2.0); 1.259 (0.6); 0.008 (0.7); 0.000 (22.1); 0.009 (0.6)

(104) TABLE-US-00003 TABLE 3 Inventive compounds of the formula (I) in which Q is Q2, W is CY, R is substituted phenyl and R.sup.7 is methyl. Table 3 contains 454 compounds (3- 1 to 3-454) in which X, Y and Z are as defined in examples 1-1 to 1-454 of table 1, and examples cited hereinafter: embedded image Physical data No. X Y Z V (.sup.1H-NMR, DMSO-d.sub.6, 400 MHz) 3-95 Me F SMe H 7.95 (s, 1H), 7.63 (d, 2H), 7.19 (dd, 2H), 3.86 (s, 3H), 2.50 (s, 6H), 2.24 (d, 6H) 3-143 Me SMe CF.sub.3 H 7.99 (s, 1H), 7.94 (d, 2H), 7.71 (d, 2H), 3.95 (s, 3H), 2.64 (s, 6H), 2.22 (d, 6H) 3-146 Me SEt CF.sub.3 H .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 7.757 (4.6); 7.602 (1.7); 7.582 (2.5); 7.520 (0.4); 7.489 (2.2); 7.469 (1.6); 7.272 (0.3); 7.271 (0.4); 7.270 (0.5); 7.269 (0.7); 7.2683 (0.8); 7.2675 (1.0); 7.267 (1.2); 7.261 (75.4); 7.2534 (0.8); 7.2526 (0.7); 7.252 (0.7); 7.251 (0.6); 7.250 (0.5); 7.249 (0.5); 7.248 (0.4); 7.247 (0.4); 7.246 (0.3); 6.998 (0.4); 3.868 (13.3); 2.899 (1.4); 2.757 (0.4); 2.738 (16.0); 2.716 (1.3); 2.697 (3.7); 2.679 (3.8); 2.660 (1.3); 1.561 (1.0: 1.233 (0.5); 1.215 (1.0); 1.201 (5.0); 1.182 (10.3); 1.164 (4.8); 0.008 (0.8); 0.006 (0.4); 0.005 (0.5); 0.004 (0.7) 3-202 Et SMe CF.sub.3 H 3-470 OMe CH.sub.2-2H-tetrazol-2- Cl H 8.49 (s, 2H), 7.76 (s, 1H), yl 7.58 (d, 2H), 7.28 (d, 2H), 5.91 (s, 2H), 3.93 (s, 6H), 3.79 (s, 3H) 3-475 Cl SO.sub.2Et CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.985 (2.4); 7.964 (3.0); 7.797 (2.2); 7.776 (1.9); 7.744 (5.8); 7.267 (0.8); 7.261 (71.7); 4.148 (0.6); 4.131 (1.7); 4.113 (1.7); 4.095 (0.6); 3.940 (16.0); 3.923 (0.7); 3.867 (0.7); 3.835 (0.6); 3.500 (1.7); 3.481 (5.6); 3.462 (5.7); 3.444 (1.8); 2.097 (0.6); 2.045 (8.1); 1.455 (0.5); 1.450 (0.5); 1.438 (5.8); 1.419 (12.6); 1.401 (5.5); 1.277 (2.6); 1.266 (1.0); 1.259 (5.3); 1.241 (2.4); 0.882 (1.7); 0.864 (0.6); 0.008 (1.0); 0.000 (30.6); 0.009 (0.9) 3.476 Cl vinyl SMe H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.876 (3.7); 7.434 (2.2); 7.433 (2.2); 7.413 (2.3); 7.412 (2.4); 7.261 (24.0); 6.999 (2.4); 6.978 (2.2); 6.519 (1.1); 6.490 (1.2); 6.474 (1.2); 6.446 (1.3); 5.737 (2.4); 5.734 (2.5); 5.708 (2.3); 5.705 (2.4); 5.564 (2.5); 5.561 (2.4); 5.519 (2.3); 5.516 (2.2); 3.908 (12.0); 2.416 (16.0); 1.255 (0.8); 0.000 (7.3) 3-477 Cl CH.sub.2OMe OMe H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.804 (2.4); 7.602 (2.0); 7.581 (2.1); 7.268 (0.5); 7.2674 (0.6); 7.2666 (0.7); 7.266 (0.8); 7.265 (1.0); 7.259 (75.8); 7.255 (0.8); 7.254 (0.5); 6.802 (1.4); 6.780 (1.4); 5.298 (0.9); 4.576 (5.0); 3.873 (6.8); 3.865 (10.0); 3.325 (16.0); 1.536 (7.0); 0.008 (0.9); 0.000 (30.4); 0.009 (0.9) 3-479 Cl C(O)-c-Pr Me H 7.84 (s, 1H), 7.47 (d, 2H), 7.15 (d, 2H), 3.89 (s, 3H), 3.25 (s, 6H), 2.14-2.10 (m, 2H), 1.32-1.28 (m, 4H), 1.14- 1.09 (m, 4H) 3-480 Cl CH(OMe)-i-Pr Cl H Example 3-480: .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.689 (4.9); 7.519 (0.7); 7.385 (1.6); 7.365 (3.9); 7.350 (0.6); 7.340 (4.9); 7.319 (2.0); 7.260 (127.0); 6.996 (0.7); 4.634 (1.0); 4.612 (1.1); 3.905 (7.4); 3.154 (13.8); 2.534 (0.6); 1.154 (16.0); 1.138 (15.6); 0.659 (3.7); 0.646 (3.9); 0.008 (1.3); 0.000 (44.3); 0.009 (1.3) 3-486 Cl 2-methylpyridin-3-yl Me H Example 3-486; .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 8.606 (1.7); 8.593 (1.7); 7.764 (3.7); 7.756 (3.3); 7.519 (0.9); 7.514 (2.2); 7.509 (1.8); 7.494 (2.6); 7.489 (2.2); 7.350 (1.4); 7.334 (1.9); 7.300 (1.9); 7.311 (0.6); 7.284 (3.4); 7.274 (2.3); 7.261 (125.8); 7.244 (1.1); 6.997 (0.7); 3.939 (2.5); 3.908 (1.1); 3.873 (14.3); 2.320 (1.4); 2.298 (1.8); 2.271 (0.6); 2.218 (7.8); 2.206 (8.0); 2.140 (0.6); 2.089 (0.5); 2.061 (1.1); 2.038 (1.9); 2.032 (1.6); 2.013 (16.0); 0.008 (1.6); 0.000 (45.1); 0.009 (1.1) 3-487 Cl 3-methyl-4,5- SMe H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): dihydro-1,2-oxazol- 7.926 (3.8); 7.912 (3.8); 5-yl 7.522 (0.6); 7.463 (3.0); 7.453 (2.9); 7.442 (3.5); 7.433 (3.2); 7.273 (0.5); 7.272 (0.6); 7.269 (1.0); 7.263 (115.7); 7.104 (3.5); 7.083 (3.1); 6.999 (0.6); 6.152 (1.0); 6.141 (1.0); 6.123 (2.4); 6.112 (2.5); 6.093 (1.0); 6.082 (1.0); 4.131 (0.8); 4.113 (0.8); 3.954 (1.0); 3.928 (0.6); 3.922 (10.8); 3.919 (10.7); 3.910 (0.5); 3.181 (0.9); 3.178 (1.0); 3.172 (1.1); 3.170 (1.1); 3.162 (1.1); 3.160 (1.1); 3.149 (1.8); 3.143 (1.2); 3.140 (1.1); 3.132 (1.1); 3.130 (1.0); 3.121 (1.0); 3.119 (1.1); 2.483 (15.7); 2.481 (16.0); 2.473 (1.6); 2.468 (0.8); 2.465 (0.9); 2.348 (0.5); 2.336 (0.5); 2.094 (1.7); 2.075 (12.2); 2.072 (12.0); 2.045 (3.9); 1.583 (1.1); 1.333 (0.5); 1.284 (0.8); 1.277 (1.3); 1.259 (4.1); 1.243 (1.4); 1.241 (1.3); 1.226 (0.7); 0.880 (0.7); 0.008 (0.6); 0.000 (24.6); 0.009 (0.7) 3-490 Cl H F Me 7.99 (s, 1H), 7.72 (d, 2H), 7.47 (d, 2H), 3.90 (s, 3H), 2.23 (s, 6H) 3-491 Br CH.sub.2OMe SO.sub.2Me H 3-492 Br F CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.775 (1.7); 7.428 (0.5); 7.2674 (0.5); 7.2666 (0.6); 7.266 (0.7); 7.265 (0.9); 7.264 (1.2); 7.260 (71.3); 7.255 (0.5); 3.957 (5.7); 1.539 (16.0); 0.008 (0.8); 0.000 (27.8); 0.009 (0.8) 3-493 Br 1H-pyrazol-1-yl Cl H 7.84 (d, 2H), 7.81 (s, 1H), 7.60 (d, 2H), 7.56 (d, 2H), 7.53 (d, 2H), 6.53 (t, 2H), 3.91 (s, 3H), 3-494 I SMe H Me .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 7.881 (3.1); 7.518 (1.2); 7.309 (0.5); 7.2803 (0.3); 7.2795 (0.4); 7.279 (0.4); 7.278 (0.4); 7.277 (0.4); 7.2763 (0.5); 7.2755 (0.5); 7.275 (0.5); 7.274 (0.6); 7.273 (0.6); 7.272 (0.7); 7.2714 (0.8); 7.2705 (0.9); 7.270 (1.0); 7.269 (1.1); 7.268 (1.3); 7.2673 (1.4); 7.2665 (1.8); 7.266 (2.1); 7.265 (2.8); 7.264 (3.6); 7.263 (4.7); 7.260 (208.2); 7.254 (4.4); 7.253 (3.7); 7.2523 (3.1); 7.2515 (2.6); 7.251 (2.2); 7.250 (2.0); 7.249 (1.6); 7.248 (1.5); 7.2474 (1.3); 7.2466 (1.2); 7.246 (1.0); 7.245 (1.0); 7.244 (0.9); 7.2433 (0.8); 7.2425 (0.7); 7.242 (0.7); 7.241 (0.6); 7.240 (0.6); 7.239 (0.5); 7.2384 (0.4); 7.2376 (0.4); 7.237 (0.4); 7.236 (0.4); 7.235 (0.4); 7.2343 (0.4); 7.2336 (0.4); 7.104 (1.7); 7.101 (1.8); 6.996 (1.2); 6.824 (1.7); 6.820 (1.7); 4.113 (0.3); 3.973 (10.2); 3.887 (0.4); 2.435 (0.4); 2.425 (0.5); 2.408 (16.0); 2.332 (11.1); 2.043 (1.6); 1.540 (91.4); 1.276 (0.6); 1.264 (0.4); 1.258 (1.1); 1.240 (0.5); 0.882 (0.7); 0.008 (1.9) 3-495 CH.sub.2OMe SMe CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.722 (2.6); 7.681 (1.2); 7.660 (2.0); 7.606 (1.5); 7.585 (0.9); 7.261 (24.0); 5.299 (1.1); 5.114 (5.9); 3.849 (8.0); 3.369 (16.0); 2.251 (12.5); 1.371 (1.1); 1.333 (1.2); 1.285 (2.3); 1.256 (2.9); 0.000 (9.1) 3-500 SMe 3-methyl-4,5- Cl H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): dihydro-1,2-oxazol- 7.775 (2.6); 7.759 (2.3); 5-l 7.520 (0.5); 7.438 (1.9); 7.432 (1.7); 7.418 (3.1); 7.411 (2.5); 7.359 (2.0); 7.339 (2.4); 7.319 (1.0); 7.261 (90.4); 6.542 (0.7); 6.531 (0.8); 6.513 (1.8); 6.501 (1.5); 6.484 (0.8); 6.473 (0.8); 3.971 (7.1); 3.966 (8.5); 3.268 (2.1); 3.239 (1.9); 3.229 (1.2); 2.458 (1.0); 2.348 (12.9); 2.342 (14.9); 2.133 (0.9); 2.101 (1.1); 2.089 (16.0); 2.045 (0.7); 1.560 (1.0); 1.259 (0.8); 0.008 (0.9); 0.000 (26.7); 0.009 (0.7)

(105) TABLE-US-00004 TABLE 4 Inventive compounds of the formula (I) in which Q is Q3, W is CY, R is substituted phenyl and R.sup.8 is methyl. Table 4 contans 454 compounds (4- 1 to 4-454 ) in which X, Y and Z are as defined in examples 1-1 to 1-454 of table 1. embedded image Physical data (.sup.1H-NMR, DMSO-d.sub.6, 400 Nr. X Y Z V MHz) 4-35 NO.sub.2 H F H 8.26 (dd, 2H), 7.99 (dd, 2H), 7.88 (dd, 2H), 1.52 (s, 3H) 4-36 NO.sub.2 H Cl H 8.22 (dd, 2H), 7.73 (dd, 2H), 7.49 (d, 2H), 2.48 (s, 3H) 4-144 Me SOMe CF.sub.3 H 7.61 (2d, 2H), 7.49 (2d, 2H), 2.96 (s, 6H), 2.93 (s, 6H), 2.41 (s, 3H) 4-157 Me NH.sub.2 SO.sub.2Me H 7.45 (d, 2H), 6.98 (d, 2H), 5.99 (s, 4H), 3.10 (s, 6H), 2.45 (s, 3H), 1.99 (s, 6H) 4-185 Me SO.sub.2Me SO.sub.2Me H 8.37 (d, 2H), 8.18 (d, 2H), 3.56 (s, 6H), 3.51 (s, 6H), 2.69 (s, 3H) 4-187 Me SEt SO.sub.2Me H .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 8.121 (2.2); 8.101 (2.4); 7.520 (0.7); 7.518 (0.7); 7.464 (2.6); 7.443 (2.5); 7.268 (0.5); 7.267 (0.6); 7.261 (114.8); 7.259 (126.6); 7.251 (1.3); 7.250 (1.1); 7.249 (1.0); 7.2484 (0.9); 7.2476 (0.8); 7.247 (0.7); 7.246 (0.6); 7.245 (0.5); 7.2443 (0.5); 7.2435 (0.5); 7.243 (0.4); 7.242 (0.4); 7.241 (0.4); 7.240 (0.4); 7.239 (0.3); 6.997 (0.7); 6.996 (0.7); 5.298 (0.7); 3.506 (0.5); 3.486 (0.5); 3.436 (16.0); 3.047 (0.3); 2.921 (0.3); 2.911 (1.2); 2.893 (3.8); 2.874 (3.9); 2.856 (1.3); 2.739 (13.3); 2.628 (0.4); 2.433 (7.9); 2.432 (8.1); 1.532 (44.2); 1.531 (47.6); 1.312 (0.4); 1.280 (4.1); 1.261 (8.3); 1.243 (3.9); 0.010 (1.3); 0.008 (1.6); 0.001 (47.4); 0.000 (52.7) 4-188 Me SOEt SO.sub.2Me H .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 8.105 (1.8); 8.085 (2.0); 8.045 (1.3); 8.025 (1.5); 7.584 (2.3); 7.564 (2.1); 7.414 (2.3); 7.394 (2.1); 7.261 (31.7); 3.442 (16.0); 3.418 (0.8); 3.399 (0.3); 3.395 (0.4); 3.338 (12.4); 3.242 (0.7); 3.223 (0.8); 3.210 (0.6); 3.190 (0.6); 2.908 (6.3); 2.890 (1.9); 2.879 (1.7); 2.871 (1.7); 2.861 (1.6); 2.852 (0.7); 2.842 (0.5); 2.832 (0.4); 2.726 (11.6); 2.437 (15.9); 2.043 (1.3); 1.552 (10.7); 1.53 7(3.2); 1.518 (6.6); 1.499 (3.0); 1.273 (4.0); 1.254 (8.5); 1.236 (3.7); 0.008 (0.5) 4-199 CH.sub.2O(CH.sub.2).sub.2OMe NH(CH.sub.2).sub.3OMe SO.sub.2Me H 7.74 (d, 2H), 7.12 (d, 2H), 4.63 (s, 4H), 3.59-3.47 (m, 12H), 3.39 (s, 6H), 3.35 (s, 6H), 3.26 (t, 4H), 3.09 (s, 6H), 2.45 (s, 3H), 1.94-1.87 (m, 4H) 4-201 Et SO.sub.2Me Cl H .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 7.494 (2.1); 7.474 (3.3); 7.406 (3.0); 7.385 (1.9); 7.262 (8.9); 5.299 (5.8); 3.352 (0.6); 3.342 (16.0); 3.263 (0.6); 3.244 (1.7); 3.226 (1.7); 3.208 (0.6); 2.413 (8.1); 2.043 (1.3); 1.550 (2.5); 1.325 (2.7); 1.307 (6.2); 1.288 (2.7); 1.276 (0.5); 1.258 (0.8); 1.240 (0.4); 0.000 (3.8) 4-205 Et NH(CH.sub.2).sub.2OMe SO.sub.2Me H 7.79 (d, 2H), 6.96 (d, 2H), 3.60 (t, 4H), 3.40 (s, 6H), 3.38 (t, 4H), 3.20 (s, 6H), 2.75 (q, 4H), 2.40 (s, 3H), 1.21 (t, 6H) 4-358 SMe SMe F H 7.30 (dd, 2H), 7.07 (dd, 2H), 2.50 (s, 6H), 2.48 (s, 3H), 2.39 (s, 6H) 4-430 Me CH.sub.2SMe CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.506 (1.6); 7.485 (2.0); 7.337 (1.8); 7.317 (1.4); 7.265 (0.6); 7.264 (0.8); 7.263 (1.0); 7.260 (45.6); 3.805 (5.7); 2.608 (0.6); 2.540 (14.0: 2.424 (14.9); 2.387 (0.6); 2.189 (0.5); 2.163 (0.8); 2.115 (16.0); 1.535 (5.3); 0.008 (0.5); 0.000 (18.7) 4-448 Me NMe.sub.2 CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.454 (1.0); 7.433 (1.2); 7.301 (1.1); 7.281 (0.9); 7.260 (35.3); 2.692 (16.0); 2.430 (8.0); 2.287 (8.3); 1.539 (14.4); 0.000 (12.0) 4-449 Me NHMe CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.364 (2.0); 7.343 (2.2); 7.260 (43.3); 7.067 (1.9); 7.047 (1.7); 2.736 (13.1); 2.421 (14.5); 2.352 (16.0: 1.543 (0.8); 1.255 (1.0); 0.000 (14.9) 4-451 Me SMe Me H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.302 (1.4); 7.2683 (1.7); 7.260 (14.1); 7.073 (1.2); 7.053 (1.0); 2.554 (8.7); 2.497 (8.1); 2.404 (8.4); 2.243 (0.7); 2.090 (16.0); 1.546 (1.7); 1.366 (0.8); 0.000 (4.8) 4-452 Me SEt OMe H 7.48 (d, 2H), 6.66 (d, 2H), 3.88 (s, 6H), 2.69 (q, 4H), 2.51 (s, 6H), 2.39 (s, 3H), 1.01 (t, 6H) 4-457 Me SMe OEt Me .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 7.396 (1.7); 7.374 (1.8); 7.265 (0.4); 7.260 (16.4); 6.647 (1.3); 6.625 (1.3); 5.298 (1.1); 4.125 (0.8); 4.107 (2.5); 4.090 (2.6); 4.072 (0.8); 2.696 (0.8); 2.522 (0.4); 2.505 (0.4); 2.495 (9.4); 2.481 (1.3); 2.396 (1.5); 2.392 (7.8); 2.383 (0.4); 2.357 (1.4); 2.325 (0.5); 2.248 (0.5); 2.231 (0.7); 2.228 (0.4); 2.221 (16.0); 1.528 (0.6); 1.510 (0.4); 1.500 (2.9); 1.492 (0.5); 1.482 (6.3); 1.465 (2.8) 4-460 Me SMe H Me 4-466 Et SEt CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.607 (2.9); 7.586 (3.5); 7.392 (2.4); 7.372 (2.0); 7.260 (39.8); 3.143 (1.0); 3.124 (3.5); 3.106 (3.6); 3.087 (1.1); 2.745 (1.4); 2.726 (4.5); 2.708 (4.6); 2.689 (1.5); 2.415 (16.0); 1.538 (14.0); 1.292 (4.5); 1.273 (10.9); 1.255 (4.9); 1.251 (6.6); 1.232 (12.3); 1.213 (5.6); 0.008 (0.5); 0.000 (17.2); 0.009 (0.5) 4-469 OMe CH.sub.2OMe Cl H 7.42 (d, 2H), 7.35 (d, 2H), 4.38 (s, 4H), 3.92 (s, 6H), 3.40 (s, 6H), 2.42 (s, 3H) 4-470 OMe CH.sub.2-2H-tetrazol-2- Cl H 8.49 (s, 2H), 7.53 (d, 2H), yl 7.26 (d, 2H), 5.85 (s, 4H), 3.93 (s, 6H), 2.39 (s, 3H) 4-471 OEt SMe CF.sub.3 H 7.51 (d, 2H), 7.49 (d, 2H), 4.22 (q, 4H), 2.44 (s, 3H), 2.30 (s, 6H), 1.46 (t, 6H) 4-477 Cl CH.sub.2OMe OMe H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.540 (2.1); 7.519 (2.4); 7.260 (30.9); 6.805 (1.5); 6.783 (1.4); 4.565 (5.4); 3.866 (10.5); 3.326 (16.0); 2.419 (7.1); 1.539 (1.2); 0.000 (11.9) 4-481 Cl CH.sub.2ONCH.sub.2 Cl H 4-482 Cl CH.sub.2ONCHMe Cl H 4-483 Cl CH.sub.2ONCMe.sub.2 Cl H 4-487 Cl 3-methyl-4,5- SMe H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): dihydro-1,2-oxazol- 7.520 (0.7); 7.414 (2.6); 7.401 5-yl (2.3); 7.393 (3.0); 7.380 (2.6); 7.273 (0.5); 7.2724 (0.5); 7.2716 (0.6); 7.271 (0.7); 7.270 (0.7); 7.269 (0.9); 7.2684 (1.1); 7.2676 (1.2); 7.267 (1.4); 7.266 (1.7); 7.265 (2.3); 7.261 (126.8); 7.083 (3.0); 7.063 (2.6); 6.997 (0.7); 6.137 (0.8); 6.129 (0.9); 6.108 (2.0); 6.099 (2.1); 6.078 (0.9); 6.070 (0.9); 4.149 (1.1); 4.131 (3.3); 4.113 (3.4); 4.095 (1.1); 3.175 (0.8); 3.166 (0.8); 3.159 (0.9); 3.146 (1.5); 3.139 (0.9); 3.137 (0.9); 3.130 (0.9); 3.128 (0.8); 3.118 (0.9); 2.485 (14.4); 2.476 (1.1); 2.472 (1.0); 2.469 (1.2); 2.443 (15.8); 2.319 (0.6); 2.095 (0.7); 2.080 (10.1); 2.077 (9.8); 2.045 (16.0); 1.548 (45.2); 1.277 (4.8); 1.259 (10.1); 1.241 (4.7); 0.008 (1.6); 0.006 (0.6); 0.005 (0.7); 0.004 (0.9); 0.000 (49.9); 0.005 (0.7); 0.009 (1.3) 4-495 CH.sub.2OMe SMe CF.sub.3 H .sup.1H-NMR (400.1 MHz, CDCl.sub.3): 7.664 (1.2); 7.644 (1.6); 7.500 (1.3); 7.480 (1.0); 7.259 (17.1); 5.017 (5.7); 3.405 (0.4); 3.392 (16.0); 3.353 (0.4); 2.593 (0.4); 2.413 (7.7); 2.270 (0.5); 2.269 (0.4); 2.255 (11.1); 2.043 (0.6); 1.569 (0.4); 1.432 (3.8); 1.258 (0.4); 0.000 (7.2) 4-496 CH.sub.2OMe SCH.sub.2CH.sub.2OMe CF.sub.3 H

(106) TABLE-US-00005 TABLE 5 Inventive compounds of the formula (I) in which Q is Q3, W is CY, W is CY, R is substituted phenyl and R.sup.8 is chlorine. Table 5 contains 454 compounds (5-1 to 5-454) in which X, Y and Z are as defined in examples 1-1 to 1-454 of table 1, and examples cited hereinafter. embedded image Physical data Nr. X Y Z V (.sup.1H-NMR, DMSO-d.sub.6, 400 MHz) 5-451 Me SMe Me H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.350 (1.3); 7.330 (1.5); 7.260 (36.4); 7.87 (1.1); 7.067 (0.9); 2.572 (8.2); 2.505 (7.6); 2.099 (16.0); 1.536 (12.0); 0.000 (13.0) 5-462 Et SMe Br H 5-466 Et SEt CF.sub.3 H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.628 (3.9); 7.607 (4.8); 7.519 (2.2); 7.469 (3.8); 7.448 (2.9); 7.293 (2.3); 7.260 (412.7); 7.225 (0.8); 6.996 (2.2); 3.152 (1.7); 3.133 (4.9); 3.115 (5.1); 3.096 (1.7); 2.748 (2.1); 2.729 (6.2); 2.710 (6.4); 2.692 (2.1); 1.570 (1.0); 1.537 (164.7); 1.293 (6.9); 1.275 (15.5); 1.256 (8.3); 1.252 (9.0); 1.233 (16.0); 1.214 (7.3); 0.899 (1.4); 0.882 (3.9); 0.864 (1.6); 0.146 (0.7); 0.033 (1.0); 0.008 (8.6); 0.000 (170.3); 0.009 (4.5); 0.150 (0.7) 5-477 Cl CH.sub.2OMe OMe H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): 7.587 (2.0); 7.565 (2.2); 7.268 (0.5); 7.2673 (0.6); 7.2665 (0.7); 7.266 (0.9); 7.265 (1.0); 7.264 (1.3); 7.263 (1.6); 7.259 (89.9); 7.256 (1.8); 7.255 (1.2); 7.2543 (0.8); 7.2535 (0.6); 6.816 (1.4); 6.794 (1.3); 4.565 (5.0); 3.873 (9.8); 3.324 (16.0); 1.531 (10.7); 0.008 (1.1); 0.000 (36.7); 0.009 (1.0) 5-484 Cl [diethyl(oxido)- Cl H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): lambda.sup.6- 7.521 (0.6); 7.330 (20.6); sulfanylidene]amino 7.320 (0.6); 7.319 (0.6); 7.309 (26.0); 7.270 (0.7); 7.262 (100.4); 7.140 (24.3); 7.134 (0.5); 7.119 (20.6); 6.998 (0.6); 4.130 (1.3); 4.113 (1.3); 3.281 (0.7); 3.263 (2.2); 3.246 (5.4); 3.235 (4.9); 3.227 (15.9); 3.217 (15.5); 3.209 (16.0); 3.198 (16.0); 3.190 (5.3); 3.180 (5.7); 3.163 (2.2); 3.145 (0.7); 2.045 (6.0); 1.555 (20.5); 1.478 (43.4); 1.460 (97.5); 1.441 (41.6); 1.425 (0.7); 1.295 (0.6); 1.277 (2.1); 1.259 (4.5); 1.247 (0.5); 1.241 (1.9); 0.008 (1.4); 0.000 (48.1); 0.009 (1.3) 5-485 Cl (4-oxido-1,4lambda.sup.4- Cl H .sup.1H-NMR (400.0 MHz, CDCl.sub.3): oxathian-4- 7.713 (0.7); 7.692 (0.7); 7.529 ylidene)amino (0.8); 7.520 (3.7); 7.508 (0.9); 7.492 (0.6); 7.482 (1.3); 7.420 (0.6); 7.390 (1.5); 7.369 (1.0); 7.354 (1.3); 7.349 (1.8); 7.343 (47.9); 7.333 (1.4); 7.328 (2.1); 7.322 (57.2); 7.302 (0.5); 7.298 (0.6); 7.295 (0.6); 7.291 (0.9); 7.290 (0.9); 7.289 (0.8); 7.2864 (0.9); 7.2856 (1.0); 7.285 (1.0); 7.284 (1.1); 7.283 (1.2); 7.2824 (1.3); 7.2816 (1.3); 7.281 (1.4); 7.280 (1.4); 7.279 (1.6); 7.2784 (1.7); 7.2776 (1.9); 7.277 (2.0); 7.276 (2.2); 7.2752 (2.5); 7.2745 (2.5); 7.274 (2.8); 7.273 (3.1); 7.272 (3.4); 7.271 (3.4); 7.2704 (3.8); 7.2696 (4.6); 7.269 (5.7); 7.268 (5.8); 7.2673 (6.7); 7.2665 (8.2); 7.266 (9.8); 7.265 (12.3); 7.264 (17.0); 7.261 (625.8); 7.256 (6.1); 7.255 (3.7); 7.254 (2.7); 7.2534 (2.4); 7.2526 (1.8); 7.252 (1.5); 7.251 (1.4); 7.250 (1.1); 7.2494 (0.9); 7.2486 (0.9); 7.248 (1.2); 7.247 (0.7); 7.228 (0.6); 7.211 (0.5); 7.173 (0.8); 7.160 (55.2); 7.39 (45.5); 7.126 (0.6); 6.997 (3.6); 4.328 (6.6); 4.320 (8.8); 4.314 (7.6); 4.305 (7.3); 4.297 (10.0); 4.268 (11.1); 4.282 (13.5); 4.273 (10.5); 4.193 (11.4); 4.187 (13.2); 4.172 (12.2); 4.165 (13.1); 4.155 (8.3); 4.149 (2.9); 4.140 (8.7); 4.134 (8.2); 4.113 (3.2); 4.095 (1.2); 3.492 (6.3); 3.482 (5.6); 3.471 (6.1); 3.460 (11.6); 3.450 (8.6); 3.437 (7.6); 3.429 (8.2); 3.364 (1.2); 3.360 (0.9); 3.280 (10.6); 3.272 (11.4); 3.266 (10.4); 3.251 (5.2); 3.243 (7.8); 3.237 (8.3); 3.229 (7.5); 2.045 (13.8); 1.864 (0.6); 1.545 (157.1); 1.300 (1.2); 1.,277 (5.5); 1.259 (16.0); 1.241 (5.7); 1.138 (0.7); 1.085 (0.7); 1.052 (0.6); 0.880 (3.5); 0.863 (1.9); 0.853 (2.1); 0.836 (1.5); 0.146 (0.8); 0.000 (282.3); 0.006 (4.3); 0.007 (3.6); 0.008 (8.6); 0.012 (1.7); 0.150 (0.9)

(107) TABLE-US-00006 TABLE 6 Inventive compounds of the formula (I) in which Q is Q4, W is CY, R is substituted phenyl and R.sup.9 is methyl. Table 6 contains 454 compounds (6- 1 to 6-454) in which X, Y and Z are as defined in examples 1-1 to 1-454 of table 1, and examples cited hereinafter. embedded image

(108) TABLE-US-00007 TABLE 7 Inventive compounds of the formula (I) having 2 identical acyl radicals, in which Q is Q1, W is N and R.sup.6 is methyl. embedded image Physical data (.sup.1H-NMR, No. X Z V DMSO-d.sub.6, 400 MHz) 7-1 F CF.sub.3 H 7-2 Cl CF.sub.3 H 7-3 Br CF.sub.3 H 7-4 Me CF.sub.3 H 7-5 CH.sub.2OMe CF.sub.3 H 7-6 CH.sub.2CH.sub.2OCH.sub.2OMe CF.sub.3 H 7-7 CH.sub.2-1,2- CF.sub.3 H thiazolidine 1,1- dioxide 7-8 CH.sub.2-pyrrolidin-2- CF.sub.3 H one 7-9 F F H 7-10 Cl Cl H 7-11 Br Br H 7-12 CF.sub.3 CF.sub.3 H 7-13 F SO.sub.2Me H 7-14 Cl SO.sub.2Me H 7-15 Br SO.sub.2Me H 7-16 OMe OMe H

(109) TABLE-US-00008 TABLE 8 Inventive compounds of the formula (I) in which Q is Q1, W is N and R.sup.6 is ethyl. Table 8 contains 16 compounds (8-1 to 8-16) in which X, Y and Z are as defined in examples 7-1 to 7-16 of table 7. embedded image Physical data No. X Z V (.sup.1H NMR , DMSO-d.sub.6, 400 MHz) 8-16 OMe OMe H 7.91 (d, 2H), 6.45 (d, 2H), 4.30 (q, 2H), 3.86 (s, 6H), 3.85 (s, 6H), 1.45 (t, 3H)

(110) TABLE-US-00009 TABLE 9 Inventive compounds of the formula (I) in which Q is Q2, W is CY, R is substituted phenyl and R.sup.7 is methyl. Table 9 contains 16 compounds (9-1 to 9-16) in which X, Y and Z are as defined in examples 7-1 to 7-16 of table 7. embedded image

(111) TABLE-US-00010 TABLE 10 Inventive compounds of the formula (I) in which Q is Q3, W is N, R is substituted phenyl and R.sup.8 is methyl. Table 10 contains 16 compounds (10-1 to 10-16) in which X, Y and Z are as defined in examples 7-1 to 7- 16 of table 7. embedded image Physical data No. X Z V (.sup.1H-NMR, DMSO-d.sub.6, 400 MHz) 10-7 CH.sub.2-1,2- CF.sub.3 H thiazolidine 1,1- dioxide

(112) TABLE-US-00011 TABLE 11 Inventive compounds of the formula (I) in which Q is Q3, W is N, R is substituted phenyl and R.sup.8 is chlorine. Table 11 comprises 16 compounds (11-1 to 11-16) in which X, Y and Z are defined in Table 7. embedded image

(113) TABLE-US-00012 TABLE 12 Inventive compounds of the formula (I) having 2 identical acyl radicals, in which Q is Q4, W is N and R.sup.9 is methyl. Table 12 comprises 16 compounds (12-1 to 12-16) in which X, Y and Z are defined in Table 7. 0embedded image

(114) TABLE-US-00013 TABLE 13 Inventive compounds of the formula (I) in which Q is Q1, Z is methylsulfonyl, W is CH, Z is trifluoromethyl, V is hydrogen and R.sup.6 is methyl. embedded image No. R Physical data, (.sup.1H-NMR, DMSO-d.sub.6, 400 MHz) 1 Me 8.36 (s, 1H), 8.26 (d, 1H), 8.06 (d, 1H), 4.12 (s, 3H), 3.38 (s, 3H), 2.22 (s, 3H) 2 Et 3 i-Pr 4 c-Pr 5 CH.sub.2CHMe.sub.2 6 CF.sub.3 7 CH.sub.2CHF.sub.2 8 CH.sub.2CF.sub.3 9 CH.sub.2OMe 10 CH.sub.2SMe 11 CH.sub.2SO.sub.2Me 12 CH.sub.2CH.sub.2CN 13 CH.sub.2CH.sub.2OMe 14 CH.sub.2CH.sub.2OEt 15 CH.sub.2CH.sub.2OPh 16 CH.sub.2CH.sub.2SMe 17 CH.sub.2CH.sub.2S(O)Me 18 CH.sub.2CH.sub.2SO.sub.2Me 19 CH.sub.2C(O)Me 20 CH.sub.2C(O)Ph 21 CH.sub.2CO.sub.2H 22 CH.sub.2CO.sub.2Me 23 CH.sub.2CN 24 CH.sub.2C(O)Me 25 CH.sub.2CO.sub.2H 26 CH.sub.2CO.sub.2Me 27 CH.sub.2CH.sub.2CN 28 allyl 29 propargyl 30 phenyl 31 4-Cl-phenyl 8.44 (d, 1H), 8.40 (s, 1H), 8.31 (d, 1H), 7.63 (d, 2H), 7.52 (d, 2H), 4.22 (s, 3H), 3.41 (s, 3H) 32 4-OMe-Ph 8.40 (d, 1H), 8.39 (s, 1H), 8.29 (d, 1H), 7.58 (d, 2H), 6.97 (d, 2H), 4.20 (s, 3H), 3.79 (s, 3H), 3.41 (s, 3H) 33 pyridin-3-yl 34 benzyl

C. Biological Examples

(115) 1. Pre-Emergence Herbicidal Action Against Harmful Plants

(116) Seeds of monocotyledonous and dicotyledonous weed plants and crop plants are laid out in sandy loam in wood-fiber pots and covered with soil. The compounds of the invention, formulated in the form of wettable powders (WP) or as emulsion concentrates (EC), are then applied to the surface of the covering soil in the form of an aqueous suspension or emulsion at a water application rate equating to 600 to 800 I/ha, with addition of 0.2% wetting agent. After the treatment, the pots are placed in a greenhouse and kept under good growth conditions for the trial plants. The damage to the test plants is scored visually after a test period of 3 weeks by comparison with untreated controls (herbicidal activity in percent (%): 100% activity=the plants have died, 0% activity=like control plants). In this case, for example, compound Nos. 1-086, 1-028, 1-206, 1-447, 1-448, 1-449, 1-454, 1-458, 1-470, 1-471, 1-472, 1-477, 1-487, 2-477, 2-480, 2-500, 3-143, 3-475, 3-491, 4-188, 4-495, 4-430, 4-496, 13-001, 13-031 and 13-032, at an application rate of 320 g/ha, each show at least 80% efficacy against Abutilon theophrasti and Veronica persica.

(117) 2. Post-Emergence Herbicidal Action Against Harmful Plants

(118) Seeds of monocotyledonous and dicotyledonous weed and crop plants are laid out in sandy loam soil in wood-fiber pots, covered with soil and cultivated in a greenhouse under good growth conditions. 2 to 3 weeks after sowing, the test plants are treated at the one-leaf stage. The compounds of the invention, formulated in the form of wettable powders (WP) or as emulsion concentrates (EC), are then sprayed onto the green parts of the plants in the form of an aqueous suspension or emulsion at a water application rate equating to 600 to 800 I/ha, with addition of 0.2% wetting agent. After the test plants have been left to stand in the greenhouse under optimal growth conditions for about 3 weeks, the action of the preparations is assessed visually in comparison to untreated controls (herbicidal action in percent (%): 100% activity=the plants have died, 0% activity=like control plants). In this case, for example, compound Nos. 1-028, 1-085, 1-086, 1-206, 1-447, 1-448, 1-449, 1-453, 1-457, 1-460, 1-470, 1-471, 1-472, 1-487, 2-500, 3-143, 3-146, 3-487, 3-491, 3-492, 4-144, 4-188, 13-001, 13-031 and 13-032, at an application rate of 80 g/ha, each show at least 80% efficacy against Abutilon theophrasti and Veronica persica.